EP0565377B1 - Therapeutic agents for use in the treatment of Parkinson's Disease - Google Patents

Therapeutic agents for use in the treatment of Parkinson's Disease Download PDF

Info

Publication number
EP0565377B1
EP0565377B1 EP93302780A EP93302780A EP0565377B1 EP 0565377 B1 EP0565377 B1 EP 0565377B1 EP 93302780 A EP93302780 A EP 93302780A EP 93302780 A EP93302780 A EP 93302780A EP 0565377 B1 EP0565377 B1 EP 0565377B1
Authority
EP
European Patent Office
Prior art keywords
compound
reference example
mmol
dipropylxanthine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP93302780A
Other languages
German (de)
French (fr)
Other versions
EP0565377A1 (en
Inventor
Fumio Suzuki
Junichi Shimada
Akio Ishii
Shunji Ichikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of EP0565377A1 publication Critical patent/EP0565377A1/en
Application granted granted Critical
Publication of EP0565377B1 publication Critical patent/EP0565377B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Definitions

  • the present invention relates to various xanthine derivatives and salts thereof now found to be useful in the treatment of Parkinson's disease.
  • R 1c and R 2c independently represent hydrogen, propyl, butyl, or allyl
  • R 3c represents hydrogen or lower alkyl
  • Y 1c and Y 2c independently represent hydrogen or methyl
  • Z c represents phenyl, pyridyl, imidazolyl, furyl, or thienyl unsubstituted or substituted by 1 to 3 substituents such as lower alkyl, hydroxy, lower alkoxy, halogen, amino, and nitro
  • Other compounds of Formula (B) are also known, but without any indication as to their pharmacological action, if any.
  • 8-styryl caffeine which is a compound of Formula (B) in which R 1c , R 2c , and R 3c represent methyl, Y 1c and Y 2c represent hydrogen, and Z c represents phenyl
  • R 1c , R 2c , and R 3c represent methyl
  • Y 1c and Y 2c represent hydrogen
  • Z c represents pyridyl, quinolyl, or methoxy-substituted or unsubstituted benzothiazolyl
  • xanthine derivatives of formula A have also been suggested as having utility in the treatment of Parkinson's disease, see EP-A-0374808, WO92/00297 and EP-A-0389282.
  • xanthine compounds having been discovered showing excellent therapeutic properties in the treatment of Parkinson's disease.
  • the lower alkyl means a straight-chain or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, and hexyl.
  • the aryl means an aryl group having 6 to 10 carbon atoms, such as phenyl and naphthyl.
  • heterocyclic group examples include furyl, thienyl, pyrrolyl, pyranyl, thiopyranyl, pyridyl, thiazolyl, imidazolyl, pyrimidyl, triazinyl, indolyl, quinolyl, purinyl, and benzothiazolyl.
  • the substituted aryl, such as the substituted naphthyl, and the substituted heterocyclic ring each has 1 to 3 independently-selected substituents. Examples of the substituents are lower alkyl, hydroxy, lower alkoxy, halogen, nitro, and amino.
  • the lower alkyl and the alkyl moiety of the lower alkoxy have the same meaning as the lower alkyl defined above.
  • the halogen includes fluorine, chlorine, bromine, and iodine.
  • compositions (I) include pharmaceutically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts.
  • Examples of the pharmaceutically acceptable acid addition salts are inorganic acid addition salts such as hydrochloride, sulfate, and phosphate, and organic acid addition salts such as acetate, maleate, fumarate, tartrate, and citrate.
  • Examples of the pharmaceutically acceptable metal salts are alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminium salt, and zinc salt.
  • Examples of the pharmaceutically acceptable ammonium salts are ammonium salt and tetramethyl ammonium salt.
  • Examples of the pharmaceutically acceptable organic amine addition salts are salts with morpholine and piperidine.
  • Examples of the pharmaceutically acceptable amino acid addition salts are salts with lysine, glycine, and phenylalanine.
  • Compounds (I) can also be produced according to the methods described in, for example, Japanese Published Unexamined Patent Application No. 26516/72; J. Med. Chem., 34 , 1431 (1991); Chem. Ber., 119 , 1525 (1986); and Chem. Abst., 60 , 1741h (1964).
  • Compound (I-b) [Compound (I) in which R 3 is hydrogen] can be prepared by the following reaction steps:
  • R 1 , R 2 , and R 4 have the same meanings as defined above.
  • a uracil derivative (II) obtained by a known method is allowed to react with either a carboxylic acid (III) or a reactive derivative thereof to give Compound (IV).
  • the reactive derivative of the carboxylic acid (III) are acid halides such as acid chloride and acid bromide, active esters such as p-nitrophenyl ester and N-oxysuccinimide, commercially available acid anhydrides, acid anhydrides produced by using carbodiimides such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, diisopropyl carbodiimide and dicyclohexyl carbodiimide, and mixed acid anhydrides with monoethyl carbonate or monoisobutyl carbonate. If the carboxylic acid (III) is used, the reaction is completed in 10 minutes to 5 hours at 50 to 200°C without using a solvent.
  • a reactive derivative of the carboxylic acid (III) is used, the reaction can be carried out according to a conventional method employed in peptide chemistry. That is, Compound (II) and a derivative of the carboxylic acid (III) are allowed to react in a solvent, preferably in the presence of an additive or a base, to give Compound (IV).
  • the solvent are halogenated hydrocarbons such as methylene chloride, chloroform, and ethylene dichloride, ethers such as dioxane and tetrahydrofuran, dimethylformamide, dimethylsulfoxide, and water.
  • An example of the additive is 1-hydroxybenzotriazole.
  • Examples of the base are pyridine, triethylamine, 4-dimethylaminopyridine, and N-methylmorpholine.
  • the reaction is completed in 0.5 to 24 hours at -80 to 50°C.
  • the reactive derivative may be formed in the reaction system and then used without being isolated.
  • Compound (I-b) can be obtained by reaction of Compound (IV) carried out in any of the following manners: in the presence of a base (Method A); by treatment with a dehydrating agent (Method B); or by heating (Method C).
  • Method A the reaction is carried out in a solvent in the presence of a base such as an alkali metal hydroxide (e.g. sodium hydroxide and potassium hydroxide).
  • a base such as an alkali metal hydroxide (e.g. sodium hydroxide and potassium hydroxide).
  • a base such as an alkali metal hydroxide (e.g. sodium hydroxide and potassium hydroxide).
  • a base such as an alkali metal hydroxide (e.g. sodium hydroxide and potassium hydroxide).
  • a base such as an alkali metal hydroxide (e.g. sodium hydroxide and potassium hydroxide).
  • water lower alcohols such as methanol and ethanol, ethers such as di
  • Method B the reaction is carried out in an inert solvent or in the absence of a solvent using a dehydrating agent such as a thionyl halide (e.g. thionyl chloride) and a phosphorus oxyhalide (e.g. phosphorus oxychloride).
  • a dehydrating agent such as a thionyl halide (e.g. thionyl chloride) and a phosphorus oxyhalide (e.g. phosphorus oxychloride).
  • a dehydrating agent such as a thionyl halide (e.g. thionyl chloride) and a phosphorus oxyhalide (e.g. phosphorus oxychloride).
  • the inert solvent are halogenated hydrocarbons such as methylene chloride, chloroform and ethane dichloride, dimethylformamide, and dimethylsulfoxide.
  • Method C the reaction is carried out in a polar solvent such as dimethylformamide, dimethylsulfoxide, and Dowtherm A (Dow Chemicals). The reaction is completed in 10 minutes to 5 hours at 50 to 200°C.
  • a polar solvent such as dimethylformamide, dimethylsulfoxide, and Dowtherm A (Dow Chemicals).
  • Compound (II) is allowed to react with an aldehyde (V) to give a Schiff's base (VI).
  • a reaction solvent mixtures of acetic acid and a lower alcohol such as methanol or ethanol may be used. The reaction is completed in 0.5 to 12 hours at -20 to 100°C.
  • Compound (VI) is oxidatively cyclized in an inert solvent in the presence of an oxidizing agent to form Compound (I-b).
  • the oxidizing agent are oxygen, ferric chloride, cerium ammonium nitrate, and diethylazodicarboxylate.
  • the inert solvent are lower alcohols such as methanol and ethanol, halogenated hydrocarbons such as methylene chloride and chloroform, and aromatic hydrocarbons such as toluene, xylene, and nitrobenzene.
  • the reaction is completed in 10 minutes to 12 hours at 0 to 180°C.
  • Compound (I-c) (Compound (I) in which R 3 is lower alkyl or allyl] can be prepared by the following reaction step.
  • Compound (I-c) is obtained from Compound (I-b) prepared by Process 1.
  • R 3d represents lower alkyl or allyl in the definition of R 3 ; and R 1 , R 2 , and R 4 have the same meanings as defined above.
  • Compound (I-c) can be obtained by reaction of Compound (I-b) with an alkylating agent, in the presence of a base if necessary.
  • alkylating agent examples include alkyl halides such as methyl iodide and allyl bromide, dialkyl sulfates such as dimethyl sulfate, sulfonic esters such as allyl p-toluenesulfonate, and diazoalkanes such as diazomethane.
  • the base are alkali metal carbonates such as sodium carbonate and potassium carbonate, alkali metal hydrides such as sodium hydride, and alkali metal alkoxides such as sodium methoxide and sodium ethoxide. The reaction is completed in 0.5 to 24 hours at 0 to 180°C.
  • Compound (I-e) (Compound (I) in which Z is phenyl having hydroxy as substituent(s)] can be alternatively prepared by the following reaction step.
  • R 6 represents lower alkyl; p and q are integers of 1 to 3 and p ⁇ q; and R 1 , R 2 , R 3 , Y 1 , and Y 2 have the same meanings as defined above.
  • the lower alkyl in the definition of R 6 has the same meaning as defined above.
  • Compound (I-e) can be obtained by reaction of Compound (I-d) [Compound (I) in which Z is phenyl having lower alkoxy as substituent(s)] obtained by Process 1 or Process 2 with a dealkylating agent.
  • a dealkylating agent examples include boron tribromide and the complex of that with dimethyl disulfide, boron trichloride, iodotrimethylsilane, sodium ethanethiolate, sodium benzenethiolate, and hydrobromic acid.
  • a reaction solvent selected from aromatic hydrocarbons such as toluene and xylene, halogenated hydrocarbons such as methylene chloride, chloroform, and dichloroethane, dimethylformamide, acetic acid, etc. depending upon the kind of the dealkylating agent is used.
  • the reaction is completed in 10 minutes to 120 hours at -30 to 140°C.
  • Compound (I-f) [Compound (I) in which Z is phenyl having lower alkoxy as substituent(s)] can be alternatively prepared by the following reaction step.
  • R 7 represents lower alkyl
  • r is an integer of 1 to 3 and q ⁇ r
  • R 1 , R 2 , R 3 , R 6 , Y 1 , Y 2 , p, and q have the same meanings as defined above.
  • the lower alkyl in the definition of R 7 has the same meaning as defined above.
  • Compound (I-f) can be obtained from Compound (I-e) according to the method of Process 2.
  • the desired compounds in the processes described above can be isolated and purified by purification methods conventionally used in synthetic organic chemistry, for example, filtration, extraction, washing, drying, concentration, recrystallization, and various kinds of chromatography.
  • Compounds (I) and pharmaceutically acceptable salts thereof may be in the form of adducts with water or various solvents, which can also be used as the therapeutic agent of the present invention.
  • Compounds (I) are shown in Table 1, and the structures thereof are shown in Table 2.
  • MPTP 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • the experiment was performed by using several groups of 7-weeks-old male C57BL/6 mice (weighing 20 to 21 g, Japan SLC), each group consisting of 8 mice.
  • MPTP Aldrich Chemical Co., Inc.
  • a physiological saline solution (Otsuka Pharmaceutical Co., Ltd.) was intraperitoneally administered to each mouse once a day for five consecutive days at a dose of 30 mg/kg.
  • a test compound was suspended in injectable distilled water (Otsuka Phamaceutical Co., Ltd.) containing Tween 80 [polyoxyethylene (20) sorbitan monooleate].
  • Test Compound (mg/kg) Amount of Active Movements (average count ⁇ S.E.M) Normal Control MPTP (-) Test Compound (-) - 2185 ⁇ 156.2 MPTP MPTP (+) Test Compound (-) - 38 ⁇ 24.2 Compound 3 MPTP (+) Compound 3 (+) 40 228 ⁇ 82.6 Compound 4 MPTP (+) Compound 4 (+) 10 961 ⁇ 164.7
  • Haloperidol (Janssen Pharmaceutica) suspended in 0.3% CMC was intraperitoneally administered to each mouse at a dose of 1.0 mg/kg.
  • Test compounds were suspended in 0.3% CMC or in injectable distilled water (Otsuka Pharmaceutical Co., Ltd.) containing Tween 80.
  • L-DOPA Kyowa Hakko Kogyo Co., Ltd.
  • benserazide hydrochloride Karla Hakko Kogyo Co., Ltd.
  • test compound suspensions and the control suspension [0.3% CMC or injectable distilled water (Otsuka Pharmaceutical Co., Ltd.) containing Tween 80] containing no test compound were orally administered to separate groups of the mice (0.1 ml per 10 g of body weight).
  • test compound the forelimbs of each mouse and subsequently the hindlimbs of the same mouse were placed on a 4.5 cm-high, 1.0 cm-wide bar and catalepsy was estimated. All of the test compounds were orally administered at a dose of 10 mg/kg, and L-DOPA (100 mg/kg) and benserazide (25 mg/kg) were intraperitoneally administered together as a control experiment.
  • score duration of the cataleptic posture 0: forelimbs less than 5 seconds hindlimbs less than 5 seconds 1: forelimbs from 5 (inclusive) to 10 (exclusive) seconds hindlimbs less than 5 seconds 2: forelimbs 10 seconds or more hindlimbs less than 5 seconds 3: forelimbs from 5 (inclusive) to 10 (exclusive) seconds hindlimbs from 5 (inclusive) to 10 (exclusive) seconds; or forelimbs less than 5 seconds hindlimbs 10 seconds or more 4: forelimbs 10 seconds or more hindlimbs from 5 (inclusive) to 10 (exclusive) seconds; or forelimbs from 5 (inclusive) to 10 (exclusive) seconds hindlimbs 10 seconds or more 5: forelimbs 10 seconds or more hindlimbs 10 seconds or more
  • the effect of the compounds was evaluated by the total of the catalepsy scores of five mice in each group (25 points at the full).
  • the groups wherein the total score was not more than 20 points were estimated to be effective.
  • the number of the animals showing remission against catalepsy is the number of the mice for which the catalepsy score was not more than 4 points.
  • the remission rate shows the rate of decrease in total score based on that of the control group.
  • Test compounds were orally administered to groups of dd-strain male mice weighing 20 ⁇ 1 g, each group consisting of three mice. Seven days after the administration, minimum lethal dose (MLD) of each compound was determined by observing the mortality.
  • MLD minimum lethal dose
  • the MLD value of all the compounds are greater than 300 mg/kg, indicating that the toxicity of the compounds is weak. Therefore, these compounds can be safely used in a wide range of doses.
  • Compounds (I) and pharmaceutically acceptable salts thereof exhibit anti-Parkinson's syndrome effects. Thus, they are effective as therapeutic agents for Parkinson's disease.
  • Compounds (I) and pharmaceutically acceptable salts thereof can be administered as they are, or in the form of various pharmaceutical compositions.
  • the pharmaceutical compositions in accordance with the present invention can be prepared by uniformly mixing an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof, as an active ingredient, with a pharmaceutically acceptable carrier. It is desired that such pharmaceutical compositions are prepared in a unit dose form suitable for oral administration or administration through injection.
  • any useful pharmaceutically acceptable carrier can be used.
  • liquid preparations for oral administration such as suspension and syrup can be prepared using water, sugars such as sucrose, sorbitol and fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, olive oil and soybean oil, preservatives such as p-hydroxybenzoates, flavors such as strawberry flavor and peppermint, and the like.
  • Powders, pills, capsules and tablets can be prepared using excipients such as lactose, glucose, sucrose and mannitol, disintegrating agents such as starch and sodium alginate, lubricants such as magnesium stearate and talc, binders such as polyvinyl alcohol, hydroxypropyl cellulose and gelatin, surfactants such as fatty acid esters, plasticizers such as glycerin, and the like. Tablets and capsules are most useful oral unit dose forms because of the readiness of administration. For preparing tablets and capsules, solid pharmaceutical carriers are used.
  • Injectable preparations can be prepared using a carrier such as distilled water, a salt solution, a glucose solution or a mixture of a salt solution and a glucose solution.
  • a carrier such as distilled water, a salt solution, a glucose solution or a mixture of a salt solution and a glucose solution.
  • the preparations can be prepared in the form of solution, suspension or dispersion according to a conventional method by using a suitable auxiliary.
  • Compounds (I) and pharmaceutically acceptable salts thereof can be administered orally in the said dosage forms or parenterally as injections.
  • the effective dose and the administration schedule vary depending upon mode of administration, age, body weight and conditions of a patient, etc. However, generally, Compound (I) or a pharmaceutically acceptable salt thereof is administered in a daily dose of 0.01 to 25 mg/kg in 3 to 4 parts.
  • Tablets having the following composition were prepared in a conventional manner.
  • Compound 1 (40 g) was mixed with 286.8 g of lactose and 60 g of potato starch, followed by addition of 120 g of a 10% aqueous solution of hydroxypropylcellulose. The resultant mixture was kneaded, granulated, and then dried by a conventional method. The granules were refined, thus obtaining granules used to make tablets. After mixing the granules with 1.2 g of magnesium stearate, the mixture was formed into tablets each containing 20 mg of the active ingredient by using a tablet maker (Model RT-15, Kikusui) having pestles of 8 mm diameter. The composition of each tablet thus prepared is shown in Table 6. Composition of One Tablet Compound 1 20 mg Lactose 143.4 mg Potato Starch 30 mg Hydroxypropylcellulose 6 mg Magnesium Stearate 0.6 mg 200 mg
  • Fine granules having the following composition were prepared in a conventional manner.
  • Compound 2 (20 g) was mixed with 655 g of lactose and 285 g of corn starch, followed by addition of 400 g of a 10% aqueous solution of hydroxypropylcellulose. The resultant mixture was kneaded, granulated, and then dried by a conventional method, thus obtaining fine granules containing 20 g of the active ingredient in 1,000 g.
  • the composition of one pack of the fine granules is shown in Table 7.
  • Composition of One Pack of Fine Granules Compound 2 20 mg Lactose 655 mg Corn Starch 285 mg Hydroxypropylcellulose 40 mg 1,000 mg
  • Capsules having the following composition were prepared in a conventional manner.
  • Compound 1 (200 g) was mixed with 995 g of Avicel and 5 g of magnesium stearate. The mixture was put in hard capsules No. 4 each having a capacity of 120 mg by using a capsule filler (Model LZ-64, Zanashi), thus obtaining capsules each containing 20 mg of the active ingredient.
  • the composition of one capsule thus prepared is shown in Table 8.
  • Injections having the following composition were prepared in a conventional manner.
  • Compound 2 (1 g) was dissolved in 100 g of purified soybean oil, followed by addition of 12 g of purified egg yolk lecithin and 25 g of glycerine for injection.
  • the resultant mixture was made up to 1,000 ml with distilled water for injection, thoroughly mixed, and emulsified by a conventional method.
  • the resultant dispersion was subjected to aseptic filtration by using 0.2 ⁇ m disposable membrane filters, and then aseptically put into glass vials in 2 ml portions, thus obtaining injections containing 2 mg of the active ingredient per vial.
  • the composition of one injection vial is shown in Table 9.
  • Composition of One Injection Vial Compound 2 2 mg Purified Soybean Oil 200 mg Purified Egg Yolk Lecithin 24 mg Glycerine for Injection 50 mg Distilled Water for Injection 1.72 ml 2.00 ml

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Disclosed are therapeutic agents for use in the treatment of Parkinson's disease, such agents being xanthine derivatives of the Formula (I) and their pharmaceutical acceptable salts: <CHEM> where R<1>, R<2> and R<3> are each H, C1-C6 alkyl or allyl; and R<4> is cycloalkyl of 3 to 8 carbon atoms, a - (CH2)n-R<5> group where n is an cycloalkyl of 3 to 8 carbon atoms, a - (CH2)n-R<5> group where n is an integer of from 0-4 and R<5> is an aryl group of 6 to 10 carbon atoms or a heterocyclic group, such aryl or heterocyclic group optionally being substituted by up to 3 substituent(s) selected from C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halogen, nitro and amino; or a <CHEM> group, where Y<1> and Y<2> are each H or CH3 and Z is a substituted or unsubstituted aryl or heterocyclic group as defined under R<5>.

Description

The present invention relates to various xanthine derivatives and salts thereof now found to be useful in the treatment of Parkinson's disease.
Various derivatives of xanthine are known to have pharmacological activity, for example, compounds of formulae A and B:
Figure 00010001
Compounds of Formula (A), for example, in which R1b and R2b both represent propyl, R3b represents hydrogen, and R4b represents substituted or unsubstituted phenyl, aromatic heterocyclic group, cycloalkyl, styryl, or phenylethyl are known to be adenosine antagonists [J. Med. Chem., 34, 1431 (1991)], whilst compounds of Formula (B) in which R1c and R2c independently represent methyl or ethyl, R3c represents methyl, Y1c and Y2c represent hydrogen, and Zc represents phenyl or 3,4,5-trimethoxyphenyl are known stimulants of brain activity [JP-A-26516/72].
Compounds of Formula (B) in which R1c and R2c independently represent hydrogen, propyl, butyl, or allyl, R3c represents hydrogen or lower alkyl, Y1c and Y2c independently represent hydrogen or methyl, and Zc represents phenyl, pyridyl, imidazolyl, furyl, or thienyl unsubstituted or substituted by 1 to 3 substituents such as lower alkyl, hydroxy, lower alkoxy, halogen, amino, and nitro are also known to be adenosine A2 receptor antagonists [WO 92/06976]. Other compounds of Formula (B) are also known, but without any indication as to their pharmacological action, if any. For example, 8-styryl caffeine, which is a compound of Formula (B) in which R1c, R2c, and R3c represent methyl, Y1c and Y2c represent hydrogen, and Zc represents phenyl, is disclosed in Chem. Ber. 119, 1525 (1986) whilst the compound of Formula (B), in which R1c, R2c, and R3c represent methyl, Y1c and Y2c represent hydrogen, and Zc represents pyridyl, quinolyl, or methoxy-substituted or unsubstituted benzothiazolyl is disclosed in Chem. Abst. 60, 1741h (1964).
In addition to the foregoing, xanthine derivatives of formula A have also been suggested as having utility in the treatment of Parkinson's disease, see EP-A-0374808, WO92/00297 and EP-A-0389282.
In accordance with the present invention a group of xanthine compounds has been discovered showing excellent therapeutic properties in the treatment of Parkinson's disease. These are xanthine derivatives of the Formula (I):
Figure 00020001
in which R1, R2, and R3 independently represent hydrogen, lower alkyl, or allyl; and R4 represents a
Figure 00030001
group, where Y1 and Y2 independently represent hydrogen or methyl; and Z represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, and their pharmaceutically acceptable salts.
The compounds represented by Formula (I) are hereinafter referred to as Compounds (I), and the same applies to the compounds of other formula numbers.
In the definitions of the groups in Formula (I), the lower alkyl means a straight-chain or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, and hexyl. The aryl means an aryl group having 6 to 10 carbon atoms, such as phenyl and naphthyl. Examples of the heterocyclic group are furyl, thienyl, pyrrolyl, pyranyl, thiopyranyl, pyridyl, thiazolyl, imidazolyl, pyrimidyl, triazinyl, indolyl, quinolyl, purinyl, and benzothiazolyl. The substituted aryl, such as the substituted naphthyl, and the substituted heterocyclic ring each has 1 to 3 independently-selected substituents. Examples of the substituents are lower alkyl, hydroxy, lower alkoxy, halogen, nitro, and amino. The lower alkyl and the alkyl moiety of the lower alkoxy have the same meaning as the lower alkyl defined above. The halogen includes fluorine, chlorine, bromine, and iodine.
The above-mentioned pharmaceutically acceptable salts of Compounds (I) include pharmaceutically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts.
Examples of the pharmaceutically acceptable acid addition salts are inorganic acid addition salts such as hydrochloride, sulfate, and phosphate, and organic acid addition salts such as acetate, maleate, fumarate, tartrate, and citrate. Examples of the pharmaceutically acceptable metal salts are alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminium salt, and zinc salt. Examples of the pharmaceutically acceptable ammonium salts are ammonium salt and tetramethyl ammonium salt. Examples of the pharmaceutically acceptable organic amine addition salts are salts with morpholine and piperidine. Examples of the pharmaceutically acceptable amino acid addition salts are salts with lysine, glycine, and phenylalanine.
The processes for producing Compounds (I) are described below. Compounds (I) can also be produced according to the methods described in, for example, Japanese Published Unexamined Patent Application No. 26516/72; J. Med. Chem., 34, 1431 (1991); Chem. Ber., 119, 1525 (1986); and Chem. Abst., 60, 1741h (1964).
Process 1
Compound (I-b) [Compound (I) in which R3 is hydrogen] can be prepared by the following reaction steps:
Figure 00050001
(In the formulae, R1, R2, and R4 have the same meanings as defined above.)
(STEP 1)
A uracil derivative (II) obtained by a known method (for example, Japanese Published Unexamined Patent Application No. 42383/84) is allowed to react with either a carboxylic acid (III) or a reactive derivative thereof to give Compound (IV). Examples of the reactive derivative of the carboxylic acid (III) are acid halides such as acid chloride and acid bromide, active esters such as p-nitrophenyl ester and N-oxysuccinimide, commercially available acid anhydrides, acid anhydrides produced by using carbodiimides such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, diisopropyl carbodiimide and dicyclohexyl carbodiimide, and mixed acid anhydrides with monoethyl carbonate or monoisobutyl carbonate. If the carboxylic acid (III) is used, the reaction is completed in 10 minutes to 5 hours at 50 to 200°C without using a solvent.
If a reactive derivative of the carboxylic acid (III) is used, the reaction can be carried out according to a conventional method employed in peptide chemistry. That is, Compound (II) and a derivative of the carboxylic acid (III) are allowed to react in a solvent, preferably in the presence of an additive or a base, to give Compound (IV). Examples of the solvent are halogenated hydrocarbons such as methylene chloride, chloroform, and ethylene dichloride, ethers such as dioxane and tetrahydrofuran, dimethylformamide, dimethylsulfoxide, and water. An example of the additive is 1-hydroxybenzotriazole. Examples of the base are pyridine, triethylamine, 4-dimethylaminopyridine, and N-methylmorpholine. The reaction is completed in 0.5 to 24 hours at -80 to 50°C. The reactive derivative may be formed in the reaction system and then used without being isolated.
(STEP 2)
Compound (I-b) can be obtained by reaction of Compound (IV) carried out in any of the following manners: in the presence of a base (Method A); by treatment with a dehydrating agent (Method B); or by heating (Method C). In Method A, the reaction is carried out in a solvent in the presence of a base such as an alkali metal hydroxide (e.g. sodium hydroxide and potassium hydroxide). As the solvent, water, lower alcohols such as methanol and ethanol, ethers such as dioxane and tetrahydrofuran, dimethylformamide, dimethylsulfoxide, and the like may be used alone or in combination. The reaction is completed in 10 minutes to 6 hours at 0 to 180°C.
In Method B, the reaction is carried out in an inert solvent or in the absence of a solvent using a dehydrating agent such as a thionyl halide (e.g. thionyl chloride) and a phosphorus oxyhalide (e.g. phosphorus oxychloride). Examples of the inert solvent are halogenated hydrocarbons such as methylene chloride, chloroform and ethane dichloride, dimethylformamide, and dimethylsulfoxide. The reaction is completed in 0.5 to 12 hours at 0 to 180°C.
In Method C, the reaction is carried out in a polar solvent such as dimethylformamide, dimethylsulfoxide, and Dowtherm A (Dow Chemicals). The reaction is completed in 10 minutes to 5 hours at 50 to 200°C.
(STEP 3)
Compound (II) is allowed to react with an aldehyde (V) to give a Schiff's base (VI). As a reaction solvent, mixtures of acetic acid and a lower alcohol such as methanol or ethanol may be used. The reaction is completed in 0.5 to 12 hours at -20 to 100°C.
(STEP 4)
Compound (VI) is oxidatively cyclized in an inert solvent in the presence of an oxidizing agent to form Compound (I-b). Examples of the oxidizing agent are oxygen, ferric chloride, cerium ammonium nitrate, and diethylazodicarboxylate. Examples of the inert solvent are lower alcohols such as methanol and ethanol, halogenated hydrocarbons such as methylene chloride and chloroform, and aromatic hydrocarbons such as toluene, xylene, and nitrobenzene. The reaction is completed in 10 minutes to 12 hours at 0 to 180°C.
Process 2
Compound (I-c) (Compound (I) in which R3 is lower alkyl or allyl] can be prepared by the following reaction step.
Compound (I-c) is obtained from Compound (I-b) prepared by Process 1.
Figure 00080001
(In the formulae, R3d represents lower alkyl or allyl in the definition of R3; and R1, R2, and R4 have the same meanings as defined above.)
Compound (I-c) can be obtained by reaction of Compound (I-b) with an alkylating agent, in the presence of a base if necessary. Examples of the alkylating agent are alkyl halides such as methyl iodide and allyl bromide, dialkyl sulfates such as dimethyl sulfate, sulfonic esters such as allyl p-toluenesulfonate, and diazoalkanes such as diazomethane. Examples of the base are alkali metal carbonates such as sodium carbonate and potassium carbonate, alkali metal hydrides such as sodium hydride, and alkali metal alkoxides such as sodium methoxide and sodium ethoxide. The reaction is completed in 0.5 to 24 hours at 0 to 180°C.
Process 3
Compound (I-e) (Compound (I) in which Z is phenyl having hydroxy as substituent(s)] can be alternatively prepared by the following reaction step.
Figure 00090001
(In the formulae, R6 represents lower alkyl; p and q are integers of 1 to 3 and p ≧ q; and R1, R2, R3, Y1, and Y2 have the same meanings as defined above.)
The lower alkyl in the definition of R6 has the same meaning as defined above.
Compound (I-e) can be obtained by reaction of Compound (I-d) [Compound (I) in which Z is phenyl having lower alkoxy as substituent(s)] obtained by Process 1 or Process 2 with a dealkylating agent. Examples of the suitable dealkylating agent are boron tribromide and the complex of that with dimethyl disulfide, boron trichloride, iodotrimethylsilane, sodium ethanethiolate, sodium benzenethiolate, and hydrobromic acid. A reaction solvent selected from aromatic hydrocarbons such as toluene and xylene, halogenated hydrocarbons such as methylene chloride, chloroform, and dichloroethane, dimethylformamide, acetic acid, etc. depending upon the kind of the dealkylating agent is used. The reaction is completed in 10 minutes to 120 hours at -30 to 140°C.
Process 4
Compound (I-f) [Compound (I) in which Z is phenyl having lower alkoxy as substituent(s)] can be alternatively prepared by the following reaction step.
Figure 00100001
(In the formulae, R7 represents lower alkyl; r is an integer of 1 to 3 and q ≥ r; and R1, R2, R3, R6, Y1, Y2, p, and q have the same meanings as defined above.)
The lower alkyl in the definition of R7 has the same meaning as defined above.
Compound (I-f) can be obtained from Compound (I-e) according to the method of Process 2.
The desired compounds in the processes described above can be isolated and purified by purification methods conventionally used in synthetic organic chemistry, for example, filtration, extraction, washing, drying, concentration, recrystallization, and various kinds of chromatography.
In the case where a salt of Compound (I) is desired and it is produced in the form of the desired salt, it can be subjected to purification as such. In the case where Compound (I) is produced in the free state and its salt is desired, Compound (I) is dissolved or suspended in a suitable solvent, followed by addition of an acid or a base to form a salt.
Compounds (I) and pharmaceutically acceptable salts thereof may be in the form of adducts with water or various solvents, which can also be used as the therapeutic agent of the present invention.
Examples of Compounds (I) are shown in Table 1, and the structures thereof are shown in Table 2.
Compound No. Name of the Compound
1 (E)-8-(3,4-dimethoxystyryl)-7-methyl-1,3-dipropylxanthine
2 (E)-8-(3,4,5-trimethoxystyryl)caffeine
3 (E) -7-methyl-1,3-dipropyl-8-styrylxanthine
4 (E)-1,3-diethyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthine
5 (E)-7-methyl-1,3-dipropyl-8-(3,4,5-trimethoxystyryl)xanthine
6 (E)-8-(4-methoxystyryl)-7-methyl-1,3-dipropylxanthine
7 (E)-1,3-diallyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthine
8 (E)-1,3-dibutyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthine
9 (E)-1,3-dipropyl-8-(3,4,5-trimethoxystyryl) xanthine
10 (E)-8-(3,4,5-trimethoxystyryl)theophylline
11 (E)-1,3-diallyl-8-(3,4,5-trimethoxystyryl) xanthine
12 (E)-8-(4-methoxy-2,3-dimethylstyryl)-1,3-dipropylxanthine
13 (E)-8-(4-methoxy-2,3-dimethylstyryl)-7-methyl-1,3-dipropylxanthine
14 (E)-8-(2,4-dimethoxy-3-methylstyryl)-1,3-dipropylxanthine
15 (E)-8-(2,4-dimethoxy-3-methylstyryl)-7-methyl-1,3-dipropylxanthine
16 (E)-8-[2-(1,4-benzodioxan-6-yl)vinyl]-1,3-dipropylxanthine
Compound No. Name of the Compound
17 (E)-8-[2-(1,4-benzodioxan-6-yl)vinyl]-7-methyl-1,3-dipropylxanthine
18 (E)-8-(3,4-methylenedioxystyryl)-1,3-dipropylxanthine
19 (E)-7-methyl-8-(3,4-methylenedioxystyryl)-1,3-dipropylxanthine
20 (E)-1,3-dipropyl-8-(2,3,4-trimethoxystyryl)xanthine
21 (E)-7-methyl-1,3-dipropyl-8-(2,3,4-trimethoxystyryl)xanthine
22 (E)-1,3-dipropyl-8-(2,4,5-trimethoxystyryl)-xanthine
23 (E)-7-methyl-1,3-dipropyl-8-(2,4,5-trimethoxystyryl)xanthine
24 (E)-8-(2,4-dimethoxystyryl)-1,3-dipropylxanthine
25 (E)-8-(2,4-dimethoxystyryl)-7-methyl-1,3-dipropylxanthine
26 (E)-8-(4-benzyloxy-3,5-dimethoxystyryl)-1,3-dipropylxanthine
27 (E)-8-(4-benzyloxy-3,5-dimethoxystyryl)-7-methyl-1,3-dipropylxanthine
28 (E)-8-(2,3-dimethoxystyryl)-1,3-dipropylxanthine
29 (E)-8-(2,3-dimethoxystyryl)-7-methyl-1,3-dipropylxanthine
30 (E)-8-(3,4-dimethylstyryl)-1,3-dipropylxanthine
31 (E)-8-(3,4-dimethylstyryl)-7-methyl-1,3-dipropylxanthine
32 (E)-8-(3,5-dimethoxystyryl)-1,3-dipropylxanthine
Compound No. Name of the Compound
33 (E)-8-(3,5-dimethoxystyryl)-7-methyl-1,3-dipropylxanthine
34 (E)-8-(3-nitrostyryl)-1,3-dipropylxanthine
35 (E)-7-methyl-8-(3-nitrostyryl)-1,3-dipropylxanthine
36 (E)-8-(3-fluorostyryl)-1,3-dipropylxanthine
37 (E)-8-(3-fluorostyryl)-7-methyl-1,3-dipropylxanthine
38 (E)-8-(3-chlorostyryl)-1,3-dipropylxanthine
39 (E)-8-(3-chlorostyryl)-7-methyl-1,3-dipropylxanthine
40 (E)-8-(2-chlorostyryl)-1,3-dipropylxanthine
41 (E)-8-(2-chlorostyryl)-7-methyl-1,3-dipropylxanthine
42 (E)-8-(2-fluorostyryl)-1,3-dipropylxanthine
43 (E)-8-(2-fluorostyryl)-7-methyl-1,3-dipropylxanthine
44 (E)-8-(4-methoxy-2,5-dimethylstyryl)-1,3-dipropylxanthine
45 (E)-8-(4-methoxy-2,5-dimethylstyryl)-7-methyl-1,3-dipropylxanthine
46 (Z)-8-(3,4-dimethoxystyryl)-7-methyl-1,3-dipropylxanthine
47 (E)-8-(4-ethoxystyryl)-1,3-dipropylxanthine
48 (E)-8-(4-ethoxystyryl)-7-methyl-1,3-dipropylxanthine
Compound No. Name of the Compound
49 (E)-8-(4-propoxystyryl)-1,3-dipropylxanthine
50 (E)-7-methyl-8-(4-propoxystyryl)-1,3-dipropylxanthine
51 (E)-8-(4-butoxystyryl)-1,3-dipropylxanthine
52 (E)-8-(4-butoxystyryl)-7-methyl-1,3-dipropylxanthine
53 (E)-8-(3,4-dihydroxystyryl)-7-methyl-1,3-dipropylxanthine
54 (E)-8-(3,4-diethoxystyryl)-7-methyl-1,3-dipropylxanthine
55 (E)-8-(3-bromo-4-methoxystyryl)-1,3-dipropylxanthine
56 (E)-8-(3-bromo-4-methoxystyryl)-7-methyl-1,3-dipropylxanthine
57 (E)-8-(2-bromo-4,5-dimethoxystyryl)-1,3-dipropylxanthine
58 (E)-8-(2-bromo-4,5-dimethoxystyryl)-7-methyl-1,3-dipropylxanthine
59 (E)-8-(3-bromo-4,5-dimethoxystyryl)-1,3-dipropylxanthine
60 (E)-8-(3-bromo-4,5-dimethoxystyryl)-7-methyl-1,3-dipropylxanthine
61 (E)-8-[2-(4-methoxynaphthyl)vinyl]-1,3-dipropylxanthine
62 (E)-8-[2-(4-methoxynaphthyl)vinyl]-7-methyl-1,3-dipropylxanthine
63 (E)-8-(3-hydroxy-4-methoxystyryl)-7-methyl-1,3-dipropylxanthine
Figure 00150001
Figure 00160001
Figure 00170001
Figure 00180001
The pharmacological activities of Compounds (I) are shown below by experimental examples.
Experimental Example 1 Effect on Locomotor Activity of Parkinson's Disease Model in Mouse
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes symptoms of Parkinson's disease in humans [Science, 219, 979 (1983)]. It is reported that an experimental Parkinson's disease model was obtained by administering MPTP to mice [Science, 224, 1451 (1984)]. If a compound is effective on the experimental Parkinson's disease model in mouse, the compound can be expected to have a therapeutic effect on Parkinson's disease.
The experiment was performed by using several groups of 7-weeks-old male C57BL/6 mice (weighing 20 to 21 g, Japan SLC), each group consisting of 8 mice. MPTP (Aldrich Chemical Co., Inc.) dissolved in a physiological saline solution (Otsuka Pharmaceutical Co., Ltd.) was intraperitoneally administered to each mouse once a day for five consecutive days at a dose of 30 mg/kg. A test compound was suspended in injectable distilled water (Otsuka Phamaceutical Co., Ltd.) containing Tween 80 [polyoxyethylene (20) sorbitan monooleate]. L-DOPA (Kyowa Hakko Kogyo Co., Ltd.) was suspended in 0.3% CMC (sodium carboxylmethylcellulose). Thirty minutes after the final MPTP administration, the test compound suspensions and the control suspension [injectable distilled water (Otsuka Pharmaceutical Co., Ltd.) containing Tween 80] containing no test compound were orally administered to separate groups of the mice (0.1 ml per 10 g of body weight). The amount of active movements (horizontal activity) of each mouse was measured by using Automex-II (Columbus Instruments International Corp.) for the period of 30 minutes starting 30 minutes after the administration of the test compound. The effect of the compounds was evaluated by comparing the average counts of the active movements of the test compound-administered groups with those of the control groups. A significant difference test was performed by using Student's t-test.
The results are shown in Tables 3-1 to 3-5.
Group Administration Dose of Test Compound (mg/kg) Amount of Active Movements (average count ± S.E.M)
Normal Control MPTP (-)
Test Compound (-) - 1875 ± 77.7
MPTP MPTP (+)
Test Compound (-) - 207 ± 85.5
Compound 1 MPTP (+)
Compound 1 (+) 10 628 ±174.5
Compound 2 MPTP (+)
Compound 2 (+) 10 1134 ±267.0
L-DOPA MPTP (+)
L-DOPA (+) 300 561 ±271.0
Group Administration Dose of Test Compound (mg/kg) Amount of Active Movements (average count ± S.E.M)
Normal Control MPTP (-)
Test Compound (-) - 2185 ±156.2
MPTP MPTP (+)
Test Compound (-) - 38 ± 24.2
Compound 3 MPTP (+)
Compound 3 (+) 40 228 ± 82.6
Compound 4 MPTP (+)
Compound 4 (+) 10 961 ±164.7
Group Administration Dose of Test Compound (mg/kg) Amount of Active Movements (average count ± S.E.M)
Normal Control MPTP (-)
Test Compound (-) - 2255 ±203.1
MPTP MPTP (+)
Test Compound (-) - 17 ± 4.9
Compound 5 MPTP (+)
Compound 5 (+) 10 24 ± 6.5
Compound 6 MPTP (+)
Compound 6 (+) 10 34 ± 12.1
Compound 7 MPTP (+)
Compound 7 (+) 10 78 ± 48.3
Group Administration Dose of Test Compound (mg/kg) Amount of Active Movements (average count ± S.E.M)
Normal Control MPTP (-)
Test Compound (-) - 2032 ±167.4
MPTP MPTP (+)
Test Compound (-) - 55 ± 16.8
Compound 5 MPTP (+)
Compound 5 (+) 40 217 ± 84.2
Compound 6 MPTP (+)
Compound 6 (+) 40 458 ±153.7
Compound 7 MPTP (+)
Compound 7 (+) 40 310 ±119.5
Group Administration Dose of Test Compound (mg/kg) Amount of Active Movements (average count ± S.E.M)
Normal Control MPTP (-)
Test Compound (-) - 2252 ±210.1
MPTP MPTP (+)
Test Compound (-) - 18 ± 8.4
Compound 9 MPTP (+)
Compound 9 (+) 40 41 ± 18.0
Compound 10 MPTP (+)
Compound 10 (+) 40 32 ± 21.2
Compound 11 MPTP (+)
Compound 11 (+) 40 20 ± 7.1
Compound 8 MPTP (+)
Compound 8 (+) 40 43 ± 28.3
Experimental Example 2 Effect on Haloperidol-Induced Catalepsy
The experiment was performed by using several groups of 5-weeks-old male ddY mice (weighing 22 to 24 g, Japan SLC), each group consisting of 5 mice. Haloperidol (Janssen Pharmaceutica) suspended in 0.3% CMC was intraperitoneally administered to each mouse at a dose of 1.0 mg/kg. Test compounds were suspended in 0.3% CMC or in injectable distilled water (Otsuka Pharmaceutical Co., Ltd.) containing Tween 80. L-DOPA (Kyowa Hakko Kogyo Co., Ltd.) and benserazide hydrochloride (Kyowa Hakko Kogyo Co., Ltd.) were suspended in 0.3% CMC. One hour after the haloperidol administration, the test compound suspensions and the control suspension [0.3% CMC or injectable distilled water (Otsuka Pharmaceutical Co., Ltd.) containing Tween 80] containing no test compound were orally administered to separate groups of the mice (0.1 ml per 10 g of body weight). One hour after the administration of the test compound, the forelimbs of each mouse and subsequently the hindlimbs of the same mouse were placed on a 4.5 cm-high, 1.0 cm-wide bar and catalepsy was estimated. All of the test compounds were orally administered at a dose of 10 mg/kg, and L-DOPA (100 mg/kg) and benserazide (25 mg/kg) were intraperitoneally administered together as a control experiment. The catalepsy score and the standard of judgment are shown below.
score duration of the cataleptic posture
0: forelimbs less than 5 seconds
hindlimbs less than 5 seconds
1: forelimbs from 5 (inclusive) to 10 (exclusive) seconds
hindlimbs less than 5 seconds
2: forelimbs 10 seconds or more
hindlimbs less than 5 seconds
3: forelimbs from 5 (inclusive) to 10 (exclusive) seconds
hindlimbs from 5 (inclusive) to 10 (exclusive) seconds;
or forelimbs less than 5 seconds
hindlimbs 10 seconds or more
4: forelimbs 10 seconds or more
hindlimbs from 5 (inclusive) to 10 (exclusive) seconds;
or forelimbs from 5 (inclusive) to 10 (exclusive) seconds
hindlimbs 10 seconds or more
5: forelimbs 10 seconds or more
hindlimbs 10 seconds or more
The effect of the compounds was evaluated by the total of the catalepsy scores of five mice in each group (25 points at the full). The groups wherein the total score was not more than 20 points were estimated to be effective. The number of the animals showing remission against catalepsy is the number of the mice for which the catalepsy score was not more than 4 points. The remission rate shows the rate of decrease in total score based on that of the control group.
The results are shown in Table 4.
Compound Total Score Number of the Animals Showing Remission Remission Rate (%)
0.3% CMC (Control) 25 0
L-DOPA + benserazide 20 3 20
1 13 5 48
2 11 5 56
3 20 4 20
4 20 4 20
5 18 4 28
6 19 3 24
7 13 4 48
11 20 3 20
L-DOPA + benserazide 18 4 28
13 5 5 80
15 19 4 24
16 20 4 20
18 20 4 20
19 19 3 24
20 19 3 24
23 18 4 28
24 19 4 24
Compound Total Score Number of the Animals Showing Remission Remission Rate (%)
0.3% Tween 80 (Control) 25 0
L-DOPA + benserazide 18 4 28
25 12 5 52
31 18 4 28
48 6 5 76
50 19 3 24
53 20 4 20
59 19 5 24
Experimental Example 3 Acute Toxicity Test
Test compounds were orally administered to groups of dd-strain male mice weighing 20±1 g, each group consisting of three mice. Seven days after the administration, minimum lethal dose (MLD) of each compound was determined by observing the mortality.
The results are shown in Table 5.
Compound MLD (mg/kg) Compound MLD (mg/kg)
1 > 300 33 > 100
2 > 300 34 > 100
3 > 300 35 > 100
4 > 300 36 > 100
5 > 300 37 > 100
6 > 300 38 > 100
7 > 300 39 > 100
8 > 300 40 > 100
9 > 300 41 > 100
10 > 300 42 > 100
11 > 300 43 > 100
12 > 300 44 > 300
13 > 300 45 > 300
14 > 100 46 > 300
15 > 300 47 > 100
16 > 300 48 > 100
17 > 300 49 > 100
18 > 300 50 > 100
19 > 300 51 > 100
20 > 300 52 > 100
21 > 300 53 > 100
22 > 300 54 > 100
23 > 300 55 > 100
24 > 100 56 > 100
25 > 300 57 > 300
26 > 100 58 > 300
27 > 100 59 > 300
28 > 100 60 > 100
29 > 300 61 > 100
30 > 100 62 > 100
31 > 100 63 > 100
32 > 100
As shown in Table 5, the MLD value of all the compounds are greater than 300 mg/kg, indicating that the toxicity of the compounds is weak. Therefore, these compounds can be safely used in a wide range of doses.
As described above, Compounds (I) and pharmaceutically acceptable salts thereof exhibit anti-Parkinson's syndrome effects. Thus, they are effective as therapeutic agents for Parkinson's disease. Compounds (I) and pharmaceutically acceptable salts thereof can be administered as they are, or in the form of various pharmaceutical compositions. The pharmaceutical compositions in accordance with the present invention can be prepared by uniformly mixing an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof, as an active ingredient, with a pharmaceutically acceptable carrier. It is desired that such pharmaceutical compositions are prepared in a unit dose form suitable for oral administration or administration through injection.
For preparing a pharmaceutical composition for oral administration, any useful pharmaceutically acceptable carrier can be used. For example, liquid preparations for oral administration such as suspension and syrup can be prepared using water, sugars such as sucrose, sorbitol and fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, olive oil and soybean oil, preservatives such as p-hydroxybenzoates, flavors such as strawberry flavor and peppermint, and the like. Powders, pills, capsules and tablets can be prepared using excipients such as lactose, glucose, sucrose and mannitol, disintegrating agents such as starch and sodium alginate, lubricants such as magnesium stearate and talc, binders such as polyvinyl alcohol, hydroxypropyl cellulose and gelatin, surfactants such as fatty acid esters, plasticizers such as glycerin, and the like. Tablets and capsules are most useful oral unit dose forms because of the readiness of administration. For preparing tablets and capsules, solid pharmaceutical carriers are used.
Injectable preparations can be prepared using a carrier such as distilled water, a salt solution, a glucose solution or a mixture of a salt solution and a glucose solution. The preparations can be prepared in the form of solution, suspension or dispersion according to a conventional method by using a suitable auxiliary.
Compounds (I) and pharmaceutically acceptable salts thereof can be administered orally in the said dosage forms or parenterally as injections. The effective dose and the administration schedule vary depending upon mode of administration, age, body weight and conditions of a patient, etc. However, generally, Compound (I) or a pharmaceutically acceptable salt thereof is administered in a daily dose of 0.01 to 25 mg/kg in 3 to 4 parts.
Certain embodiments of the invention are illustrated in the following Examples, including the separately numbered series of "reference" Examples.
Example 1 (E)-8-(2-(1,4-Benzodioxan-6-yl)vinyl]-1,3-dipropyl-xanthine (Compound 16)
Substantially the same procedure as in Reference Example 1 was repeated using 1.35 g (5.96 mmol) of 5,6-diamino-1,3-dipropyluracil and 1.35 g (6.55 mmol) of 3-(1,4-benzodioxan-6-yl)acrylic acid. Then, the resultant crude crystals were recrystallised from ethanol/water to give 1.54 g (yield 65%) of Compound 16 as white needles.
Melting point:
>275°C
Elemental Analysis: C21H24N4O4
Calcd. (%): C, 63.62; H, 6.10; N, 14.13
Found (%): C, 63.57; H, 6.24; N, 14.36
IR (KBr) vmax (cm-1);
1693, 1636, 1582, 1511
NMR (DMSO-D6; 270 MHz) δ (ppm):
12.52(1H, brs), 7.63 (1H, d, J=16.2Hz), 7.10-7.06(2H, m), 6.95-6.86(2H, m), 4.29(4H, s), 4.15-4,10(4H m), 1.90-1.65(4H m), 1.05-0.95(6H, m)
Example 2 (E) -8- [2- (1,4-Benzodioxan-6-yl)vinyl]-7-methyl-1,3-dipropylxanthine (Compound 17)
Substantially the same procedure as in Reference Example 1 was repeated using 1.0 g (2.52 mmol) of Compound 16 obtained in Example 1 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol to give 840 mg (yield 81%) of Compound 17 as pale yellow needles.
Melting Point:
181.9-182.3°C
Elemental Analysis: C22H26N4O4
Calcd. (%): C, 64.37; H, 6.38; N, 13.64
Found (%): C, 64.56; H, 6.63; N, 13.92
IR (KBr) νmax (cm-1) :
1693, 1651, 1510, 1288
NMR (CDCl3; 270MHz) δ (ppm) :
7.67 (1H, d, J=15.5Hz), 7.10(2H, m), 6.88(1H, d, J=8.3Hz), 6.74(1H, d, J=15.5Hz), 4.30(4H, m), 4.13-3.95(4H, m), 4.03(3H, s), 1.88-1.65(4H, m), 1.03-0.94 (6H, m)
Example 3 (E)-8-(3,4-Methylenedioxystyryl)-1,3-dipropylxanthine (Compound 18)
Substantially the same procedure as in Reference Example 1 was repeated using 4.25 g (18.8 mmol) of 5,6-diamino-1,3-dipropyluracil and 4.33 g (22.6 mmol) of 3,4-methylenedioxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 4.92 g (yield 69%) of Compound 18 as a pale yellow powder.
Melting Point:
>270°C
Elemental Analysis: C20H22N4O4·0.75H2O
Calcd. (%): C, 60.50; H, 5.72; N, 14.43
Found (%): C, 60.67; H, 5.98; N, 14.15
IR (KBr) νmax (cm-1) :
1688, 1648, 1499
NMR (DMSO-d6; 270MHz) δ (ppm):
13.49(1H, brs), 7.56 (1H, d, J=16.3Hz), 7.30(1H, s), 7.07(1H, d, J=8.4Hz), 6.97-6.89(2H, m), 6.07(2H, s), 3.98 (2H, t, J=7.2Hz), 3.85(2H, t, J=7.3Hz), 1.75-1.35(4H, m), 0.95-0.80(6H, m)
Example 4 (E)-7-Methyl-8-(3,4-methylenedioxystyryl)-1,3-dipropylxanthine (Compound 19)
Substantially the same procedure as in Reference Example 1 was repeated using 3.0 g (7.85 mmol) of Compound 18 obtained in Example 3 in place of Compound B. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 2.33 g (yield 75%) of Compound 19 as a pale green powder.
Melting Point:
151.7-155.4°C
Elemental Analysis: C21H24N4O4·0.25H2O
Calcd. (%): C, 62.91; H; 6.16; N, 13.97
Found (%): C, 62.88; H, 6.25; N, 13.72
IR (KBr) νmax (cm-1):
1689, 1650, 1498, 1443
NMR (CDCl3; 270MHz) δ (ppm) :
7.70 (1H, d, J=15.6Hz), 7.10-6.95(2H, m), 6.84 (1H, d, J=7.9Hz), 6.72(1H, d, J=15.6Hz), 6.02(2H, s), 4.10(2H, t, J=7.3Hz), 4.04(3H, s), 3.97(2H, t, J=7.3Hz), 1.90-1.65(4H, m), 1.05-0.90(6H, m)
Example 5 (E)-8-[2-(4-Methoxynaphthyl)vinyl]-1,3-dipropylxanthine (Compound 61)
Substantially the same procedure as in Reference Example 1 was repeated using 3.0 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.33 g (14.6 mmol) of 3- (4-methoxynaphthyl)acrylic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 3.12 g (yield 56%) of Compound 61 as yellow needles.
Melting Point:
>280°C
Elemental Analysis: C24H26N4O3
Calcd. (%): C, 68.88; H, 6.26; N, 13.39
Found (%): C, 68.90; H, 6.38; N, 13.49
IR (KBr) νmax (cm-1):
1699, 1649, 1486, 1273
NMR (DMSO-d6; 270MHz) δ (ppm):
13.58(1H, brs), 8.43 (1H, d, J=16.5Hz), 8.36(1H, d, J=8.6Hz), 8.24(1H, d, J=8.6Hz), 7.98(1H, d, J=7.8Hz), 7.70-7.54(2H, m), 7.12-7.06(2H, m), 4.03(3H, s), 4.02-3.86(4H, m), 1.79-1.56(4H, m), 0.92(3H, s), 0.89(3H, s)
Example 6 (E)-8-[2-(4-Methoxynaphthyl)vinyl]-7-methyl-1,3-dipropylxanthine (Compound 62)
Substantially the same procedure as in Reference Example 1 was repeated using 1.6 g (3.82 mmol) of Compound 61 obtained in Example 5 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethyl acetate to give 1.25 g (yield 76%) of Compound 62 as pale yellow plates.
Melting Point:
212.6-213.9°C
Elemental Analysis: C25H28N4O3
Calcd. (%): C, 69.43; H, 6.52; N, 12.95
Found (%): C, 69.46; H, 6.68; N; 12.95
IR (KBr) νmax (cm-1):
1701, 1650, 1486, 1439, 1267
NMR (CDCl3; 270MHz) δ (ppm):
8.52(1H, d, J=15.5Hz), 8.34(1H, d, J=8.3Hz), 8.23(1H, d, J=8.6Hz), 7.77 (1H, d, J=8.3Hz), 7.66-7.52(2H, m), 6.89(1H, d, J=15.5Hz), 6.87(1H, d, J=8.3Hz), 4.18-4.11(2H, m), 4.07(3H, s), 4.06(3H, s), 4.02-3.97(2H, m), 1.95-1.64(4H, m), 1.03(3H, t, J=7.3Hz), 0.98(3H, t, J=7.3Hz)
Example 7 Tablets
Tablets having the following composition were prepared in a conventional manner.
Compound 1 (40 g) was mixed with 286.8 g of lactose and 60 g of potato starch, followed by addition of 120 g of a 10% aqueous solution of hydroxypropylcellulose. The resultant mixture was kneaded, granulated, and then dried by a conventional method. The granules were refined, thus obtaining granules used to make tablets. After mixing the granules with 1.2 g of magnesium stearate, the mixture was formed into tablets each containing 20 mg of the active ingredient by using a tablet maker (Model RT-15, Kikusui) having pestles of 8 mm diameter. The composition of each tablet thus prepared is shown in Table 6.
Composition of One Tablet
Compound 1 20 mg
Lactose 143.4 mg
Potato Starch 30 mg
Hydroxypropylcellulose 6 mg
Magnesium Stearate 0.6 mg
200 mg
Example 8 Fine Granules
Fine granules having the following composition were prepared in a conventional manner.
Compound 2 (20 g) was mixed with 655 g of lactose and 285 g of corn starch, followed by addition of 400 g of a 10% aqueous solution of hydroxypropylcellulose. The resultant mixture was kneaded, granulated, and then dried by a conventional method, thus obtaining fine granules containing 20 g of the active ingredient in 1,000 g. The composition of one pack of the fine granules is shown in Table 7.
Composition of One Pack of Fine Granules
Compound 2 20 mg
Lactose 655 mg
Corn Starch 285 mg
Hydroxypropylcellulose 40 mg
1,000 mg
Example 9 Capsules
Capsules having the following composition were prepared in a conventional manner.
Compound 1 (200 g) was mixed with 995 g of Avicel and 5 g of magnesium stearate. The mixture was put in hard capsules No. 4 each having a capacity of 120 mg by using a capsule filler (Model LZ-64, Zanashi), thus obtaining capsules each containing 20 mg of the active ingredient. The composition of one capsule thus prepared is shown in Table 8.
Composition of One Capsule
Compound 1 20 mg
Avicel 99.5mg
Magnesium Stearate 0.5mg
120 mg
Example 10 Injections
Injections having the following composition were prepared in a conventional manner.
Compound 2 (1 g) was dissolved in 100 g of purified soybean oil, followed by addition of 12 g of purified egg yolk lecithin and 25 g of glycerine for injection. The resultant mixture was made up to 1,000 ml with distilled water for injection, thoroughly mixed, and emulsified by a conventional method. The resultant dispersion was subjected to aseptic filtration by using 0.2 µm disposable membrane filters, and then aseptically put into glass vials in 2 ml portions, thus obtaining injections containing 2 mg of the active ingredient per vial. The composition of one injection vial is shown in Table 9.
Composition of One Injection Vial
Compound 2 2 mg
Purified Soybean Oil 200 mg
Purified Egg Yolk Lecithin 24 mg
Glycerine for Injection 50 mg
Distilled Water for Injection 1.72 ml
2.00 ml
Reference Example 1 (E)-8-(3,4-Dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 1)
3,4-Dimethoxycinnamic acid (2.03 g, 9.74 mmol) and 3-(3-diethylaminopropyl)-1-ethylcarbodiimide hydrochloride (2.54 g, 13.3 mmol) were added to a mixture of water (60 ml) and dioxane (30 ml) containing 5,6-diamino-1,3-dipropyluracil (U.S. Patent No. 2,602,795) (2.00 g, 8.85 mmol). The resultant solution was stirred at room temperature for 2 hours at pH 5.5. After neutralization, the reaction solution was extracted three times with 50 ml of chloroform. The combined extract was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (eluent: 2% methanol/chloroform) to give 3.47 g (yield 94%) of (E)-6-amino-5-(3,4-dimethoxycinnamoyl)amino-1,3-dipropyluracil (Compound A) as an amorphous substance.
NMR (CDCl3; 90MHz) δ (ppm) :
7.84(1H, brs), 7.50(1H, d, J=15.9Hz), 7.10-6.65(3H, m), 6.53(1H, d, J=15.9Hz), 5.75(2H, brs), 4.00-3.50(4H, m), 3.85(6H, brs), 2.00-1.40(4H, m), 1.10-0.80(6H, m)
To 3.38 g (8.13 mmol) of Compound A were added 40 ml of dioxane and 80 ml of an aqueous 1N sodium hydroxide solution, followed by heating under reflux for 10 minutes. After cooling, the solution was neutralized, and deposited crystals were collected by filtration. Then, the collected crystals were recrystallized from dimethylsulfoxide/water to give 2.49 g (yield 77%) of (E)-8-(3,4-dimethoxystyryl)-1,3-dipropylxanthine (Compound B) as white crystals.
Melting Point:
260.0-263.8°C
Elemental Analysis: C21H26N4O4
Calcd. (%): C, 63.30; H, 6.57; N, 14.06
Found (%): C, 63.29; H, 6.79; N, 14.21
IR (KBr) νmax (cm-1):
1701, 1640
NMR (DMSO-d6; 270MHz) δ (ppm) :
13.39(1H, brs), 7.59 (1H, d, J=16.7Hz), 7.26(1H, d, J=1.8Hz), 7.13(1H, dd, J=1.8, 8.6Hz), 6.98(1H, d, J=8.6Hz), 6.95(1H, d, J=16.7Hz), 3. 99(2H, t), 4.00-3.85(2H, t), 3.83(3H, s), 3.80(3H, s), 1.80-1.55(4H, m), 1.00-0.85(6H, m)
Compound B (1.20 g, 3.02 mmol) was dissolved in 20 ml of dimethylformamide. To the solution were added 1.04 g (7.55 mmol) of potassium carbonate and subsequently 0.38 ml (6.04 mmol) of methyl iodide, and the resultant mixture was stirred at 50°C for 30 minutes. After cooling, insoluble matters were filtered off, and 400 ml of water was added to the filtrate. The mixture was extracted three times with 100 ml of chloroform. The extract was washed twice with water and once with a saturated aqueous solution of sodium chloride, and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (eluent: 1% methanol/chloroform), followed by recrystallization from propanol/water to give 1.22 g (yield 98%) of Compound 1 as white needles.
Melting Point:
164.1-166.3°C
Elemental Analysis: C22H28N4O4
Calcd. (%): C, 64.06; H, 6.84; N, 13.58
Found (%): C, 64.06; H, 6.82; N, 13.80
IR (KBr) νmax (cm-1):
1692, 1657
NMR (DMSO-d6; 270MHz) δ (ppm):
7.60(1H, d, J=15.8Hz), 7.40(1H, d, 2.0Hz), 7.28(1H, dd, J=2.0, 8.4Hz), 7.18(1H, d, J=15.8Hz), 6.99(1H, d, J=8.4Hz), 4.02(3H, s), 3.99(2H, t), 3.90-3.80(2H, m), 3.85(3H, s), 3.80(3H, s), 1.80-1.55(4H, m), 1.00-0.85(6H, m)
Reference Example 2 (E)-7-Methyl-1,3-dipropyl-8-styrylxanthine (Compound 3)
5,6-Diamino-1,3-dipropyluracil (U.S. Patent No. 2,602,795) (6.0 g, 26.5 mmol) was slowly added to a mixture of methanol (360 ml) and acetic acid (15 ml) containing cinnamaldehyde (3.34 ml, 26.5 mmol) under ice cooling. The resultant mixture was stirred at room temperature for 30 minutes, followed by evaporation under reduced pressure to give 6.30 g (yield 70%) of (E)-6-amino-5-(3-phenyl-3-propenylidene)-1,3-dipropyluracil (Compound C) as an amorphous substance.
Melting Point:
159.5-161.0°C
IR (KBr) νmax (cm-1):
1687, 1593
NMR (CDCl3; 90MHz) δ (ppm) :
9.75-9.60(1H, m), 7.60-7.25(5H, m), 7.00-6.80(2H, m), 5.70(brs, 2H), 4.00-3.70(4H, m), 2.00-1.40(4H, m), 1.10-0.75(6H, m)
MS m/e (relative intensity):
340(100, M+), 130(86)
To 6.30 g (18.5 mmol) of Compound C was added 240 ml of ethanol, and the mixture was heated under reflux for 2 hours in the presence of 4.32 g (26.5 mmol) of ferric chloride. After cooling, deposited crystals were collected by filtration to give 3.61 g (yield 61%) of (E)-1,3-dipropyl-8-styrylxanthine (Compound D) as white crystals.
Melting Point:
259.3-261.0°C (recrystallised from ethanol)
Elemental Analysis: C19H22N4O2
Calcd. (%): C, 67.43; H, 6.55; N, 16.56
Found (%): C, 67.40; H, 6.61; N, 16.71
IR (KBr) νmax (cm-1):
1700, 1650, 1505
NMR (DMSO-d6) δ (ppm):
13.59(1H, brs), 7.70-7.55 (3H, m), 7.50-7.30(3H, m), 7.06(1H, d, J= 16.5Hz), 3.99(2H, t), 3.86(2H, t), 2.80-2.50(4H, m), 0.95-0.80(6H, m)
Subsequently, the same procedure as in Reference Example 1 was repeated using Compound D in place of Compound B to give 1.75 g (yield 84%) of Compound 3 as white needles.
Melting Point:
162.8-163.2°C
Elemental Analysis: C20H24N4O2
Calcd. (%): C, 68.16; H, 6.86; N, 15.90
Found (%): C, 67.94; H, 6.96; N, 16.15
IR (KBr) νmax (cm-1):
1690, 1654, 1542, 1450, 1437
NMR (CDCl3) δ (ppm):
7.79(1H, d, J=15.8Hz), 7.65-7.55(2H, m), 7.48-7.35(3H, m), 6.92(1H, d, J=15.8Hz), 4.11(2H, t), 4.06(3H, s), 3.98(2H, t), 2.00-1.60(4H, m), 1.08-0.95(6H, m)
Reference Example 3 (E)-1,3-Dipropyl-8-(3,4,5-trimethoxystyryl)xanthine (Compound 9)
3,4,5-Trimethoxycinnamic acid (5.78 g, 24.3 mmol) and 6.36 g (33.2 mmol) of 3-(3-diethylaminopropyl)-1-ethylcarbodiimide hydrochloride were added to a mixture of dioxane (150 ml) and water (75 ml) containing 5.00 g (22.1 mmol) of 5,6-diamino-1,3-dipropyluracil. The resultant solution was stirred at room temperature at pH 5.5 for one hour. After the reaction, the solution was adjusted to pH 7 and extracted three times with chloroform. The combined extract was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (eluent: 3% methanol/chloroform) to give 8.06 g (yield 82%) of (E)-6-amino-1,3-dipropyl-5-(3,4,5-trimethoxycinnamoyl)aminouracil (Compound E) as an amorphous substance.
NMR (CDCl3; 90MHz) δ (ppm):
7.85(1H, brs), 7.48(1H, d, J=15.6Hz), 6.67(2H, s), 6.56(1H, d, J=15.6Hz), 5.80(2H, brs), 4.00-3.70(4H, m), 3.89(9H, s), 1.80-1.45(4H, m), 1.15-0.80(6H, m)
To 10.02 g (22.5 mmol) of Compound E were added 100 ml of dioxane and 100 ml of an aqueous 2N sodium hydroxide solution, and the solution was heated under reflux for 10 minutes. After cooling, the solution was neutralized, and deposited crystals were collected by filtration. Then, the collected crystals were recrystallized from dioxane/water to give 6.83 g (yield 91%) of (E)-1,3-dipropyl-8-(3,4,5-trimethoxystyryl)xanthine (Compound 9) as white crystals.
Melting Point:
161.8-162.6°C
Elemental Analysis: C22H28N4O5
Calcd. (%): C, 61.66; H, 6.58; N, 13.07
Found (%): C, 61.73; H, 6.37; N, 13.08
IR (KBr) νmax (cm-1):
1702, 1643
NMR (CDCl3; 90MHz) δ (ppm):
12.87(1H, brs), 7.72(1H, d, J=16.3Hz), 6.96(1H, d, J=16.3Hz), 6.81(2H, s), 4.30-3.95(4H, m), 3.92(6H, s), 3.90(3H, s), 2.10-1.50(4H, m), 1.02(2H, t), 0.90(2H, t)
Reference Example 4 (E)-7-Methyl-1,3-dipropyl-8-(3,4,5-trimethoxystyryl)xanthine (Compound 5)
The same procedure as in Reference Example 1 was repeated using Compound 9 in place of Compound B to give 1.75 g (yield 84%) of Compound 5 as white needles.
Melting Point:
168.4-169.1°C (recrystallized from ethanol/water)
Elemental Analysis: C23H30N4O5
Calcd. (%): C, 62.42; H, 6.83; N, 12.66
Found (%): C, 62.48; H, 6.60; N, 12.70
IR (KBr) νmax (cm-1):
1698, 1659
NMR (CDCl3; 90MHz) δ (ppm):
7.71(1H, d, J=15.8Hz), 6.86(2H, s), 6.78(1H, d, J=15.8Hz), 4.30-3.95(4H, m), 4.07(3H, s), 3.93(6H, s), 3.90(3H, s), 2.05-1.50 (4H, m), 1.20-0.85 (6H, m)
Reference Example 5 (E)-8-(4-Methoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 6)
Substantially the same procedure as in Reference Example 1 was repeated using 2.00 g (8.85 mmol) of 5,6-diamino-1,3-dipropyluracil and 1.73 g (9.74 mmol) of 4-methoxycinnamic acid to give 2.29 g (overall yield 68%) of Compound 6.
Melting Point:
159.8-161.3°C (recrystallized from ethanol/water)
Elemental Analysis: C21H26N4O3
Calcd. (%): C, 65.94; H, 6.85; N, 14.64
Found (%): C, 65.92; H, 6.90; N, 14.88
IR (KBr) νmax (cm-1):
1695, 1658
NMR (DMSO-d6) δ (ppm):
7.72 (2H, d, J=8. 8Hz), 7.61(1H, d, J=15.8Hz), 7.16(1H, d, J=15.8Hz), 4.05-3.95(2H, m), 4.00(3H, s), 3.83(2H, t), 3.80 (3H, s), 1.85-1.50 (4H, m), 1.00-0.85 (6H, m)
Reference Example 6 (E)-1,3-Diallyl-8-(3,4,5-trimethoxystyryl)xanthine (Compound 11)
Substantially the same procedure as in Reference Example 3 was repeated using 3.0 g (13.5 mmol) of 1,3-diallyl-5,6-diaminouracil and 3.55 g (14.9 mmol) of 3,4,5-trimethoxycinnamic acid to give 4.48 g (yield 75%) of (E)-1,3-diallyl-6-amino-5-(3,4,5-trimethoxycinnamoyl)aminouracil (Compound F) as an amorphous substance.
NMR (CDCl3; 90MHz) δ (ppm):
7.90(1H, brs), 7.56(1H, d, J=16.0Hz), 6.71(2H, s), 6.57(1H, d, J=16.0Hz), 6.15-5.60(4H, m), 5.50-5.05(4H, m), 4.75-4.45(4H, m), 3.90(9H, s)
Substantially the same procedure as in Reference Example 3 was repeated using 4.34 g (9.82 mmol) of Compound F in place of Compound E to give 2.81 g (yield 68%) of Compound 11 as a pale yellowish green powder.
Melting Point:
253.1-255.4°C (recrystallized from dioxane)
Elemental Analysis: C22H24N4O5·1/2H2O
Calcd. (%): C, 60.96; H, 5.81; N, 12.93
Found (%): C, 61.05; H, 5.60; N, 12.91
IR (KBr) νmax (cm-1):
1704, 1645, 1583, 1510
NMR (CDCl3) δ (ppm):
12.94(1H, brs), 7.73(1H, d, J=16.3Hz), 7.05(1H, d, J=16.3Hz), 6.81(2H, s), 6.12-5.92(2H, m), 5.37-5.22(4H, m), 4.83-4.76(4H, m), 3.91(6H, s), 3.90(3H, s)
Reference Example 7 (E)-1,3-Diallyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthine (Compound 7)
Substantially the same procedure as in Reference Example 1 was repeated using 1.13 g (2.67 mmol) of Compound 11 in place of Compound B to give 620 mg (yield 53%) of Compound 7 as pale yellow needles.
Melting Point:
189.0-191.1°C (recrystallized from ethyl acetate)
Elemental Analysis: C23H26N4O5
Calcd. (%): C, 63.00; H, 5.97; N, 12.77
Found (%): C, 63.00; H, 6.05; N, 12.85
IR (KBr) νmax (cm-1):
1699, 1660
NMR (CDCl3; 90MHz) δ (ppm):
7.78(1H, d, J=16.0Hz), 6.85(2H, s), 6.84(1H, d, J=16.0Hz), 6.30-5.75(2H, m), 5.45-5.10(4H, m), 4.85-4.55(4H, m), 4.07(3H, s), 3.92(6H, s), 3.90(3H, s)
Reference Example 8 (E)-1,3-Dibutyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthine (Compound 8)
Substantially the same procedure as in Reference Example 1 was repeated using 4.75 g (18.7 mmol) of 5,6-diamino-1,3-dibutyluracil and 4.90 g (20.6 mmol) of 3,4,5-trimethoxycinnamic acid to give 5.49 g (overall yield 63%) of Compound 8 as a pale green powder.
Melting Point:
136.8-137.3°C (recrystallized from ethanol/water)
Elemental Analysis: C25H34N4O5
Calcd. (%): C, 63.81; H, 7.28; N, 11.91
Found (%): C, 63.63; H, 6.93; N, 11.99
IR (KBr) νmax (cm-1):
1692, 1659
NMR (CDCl3; 90MHz) δ (ppm):
7.68(1H, d, J=15.8Hz), 6.80(2H, s), 6.79(1H, d, J=15.8Hz), 4.30-3.90(4H, m), 4.03(3H, s), 3.95(6H, s), 3.91(3H, s), 1.90-1.10 (8H, m), 1.05-0.80 (6H, m)
Reference Example 9 (E)-8-(4-Methoxy-2,3-dimethylstyryl)-1,3-dipropylxanthine (Compound 12)
Substantially the same procedure as in Reference Example 1 was repeated using 2.31 g (10.24 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.42 g (15.4 mmol) of 4-methoxy-2,3-dimethylcinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.96 g (yield 48%) of Compound 12 as a white powder.
Melting Point:
270.7-271.3°C
Elemental Analysis: C22H28N4O3
Calcd. (%): C, 66.64; H, 7.11; N, 14.13
Found (%): C, 66.68; H, 7.20; N, 14.04
IR (KBr) νmax (cm-1):
1704, 1650, 1591, 1269
NMR (DMSO-d6; 270MHz) δ (ppm):
7.93(1H, d, J=16.3Hz), 7.57(1H, d, J=8.9Hz), 6.88(1H, d, J=8.9Hz), 6.82(1H, d, J=16.3Hz), 3.98(2H, t, J=7.1Hz), 3.86(2H, t, J=7.3Hz), 3.81(3H, s), 2.32(3H, s), 2.09(3H, s), 1.80-1.55(4H, m), 0.95-0.80(6H, m)
Reference Example 10 (E)-8-(4-Methoxy-2,3-dimethylstyryl)-7-methyl-1,3-dipropylxanthine (Compound 13)
Substantially the same procedure as in Reference Example 1 was repeated using 4.00 g (5.10 mmol) of Compound 12 obtained in Reference Example 9 in place of Compound B to give 1.73 g (yield 83%) of Compound 13 as yellow needles.
Melting Point:
171.0-173.5°C
Elemental Analysis: C23H30N4O3
Calcd. (%): C, 67.29; H, 7.36; N, 13.64
Found (%): C, 66.87; H, 7.67; N, 13.51
IR (KBr) νmax (cm-1):
1697, 1659, 1593, 1493
NMR (CDCl3; 270MHz) δ (ppm):
8.07(1H, d, J=15.3Hz), 7.46(1H, d, J=8.4Hz), 6.77(1H, d, J=8.4Hz), 6.67(1H, d, J=15.3Hz), 4.12(2H, t, J=7.3Hz), 4.03(3H, s), 3.98(2H, t, J=7.3Hz), 3.86(3H, s), 2.39(3H, s), 2.26(3H, s), 1.85-1.50(4H, m), 1.05-0.90(6H, m)
Reference Example 11 (E)-8-(2,4-Dimethoxy-3-methylstyryl)-1,3-dipropylxanthine (Compound 14)
Substantially the same procedure as in Reference Example 1 was repeated using 1.25 g (5.52 mmol) of 5,6-diamino-1,3-dipropyluracil and 1.35 g (6.08 mmol) of 2,4-dimethoxy-3-methylcinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.14 g (yield 50%) of Compound 14 as white needles.
Melting Point:
255.2-256.0°C
Elemental Analysis: C22H28N4O4
Calcd. (%): C, 64.06; H, 6.84; N, 13.58
Found (%): C, 63.77; H, 7.01; N, 13.42
IR (KBr) νmax (cm-1):
1694, 1650, 1594, 1495
NMR (DMSO-d6; 270MHz) δ (ppm):
13.54(1H, brs), 7.76 (1H, d, J=16.5Hz), 7.59(1H, d, J=8.9Hz), 6.99(1H, d, J=16.5Hz), 6.84(1H, d, J=8.9Hz), 3.99(2H, t, J=7.4Hz), 3.85(2H, t, J=7.3Hz), 3.83(3H, s), 3.70 (3H, s), 2.09(3H, s), 1.80-1.55(4H, m), 0.95-0.80 (6H, m)
Reference Example 12 (E)-8-(2,4-Dimethoxy-3-methylstyryl)-7-methyl-1,3-dipropylxanthine (Compound 15)
Substantially the same procedure as in Reference Example 1 was repeated using 1.10 g (2.67 mmol) of Compound 14 obtained in Reference Example 11 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol/2-propanol to give 620 mg (yield 55%) of Compound 15 as pale yellow grains.
Melting Point:
191.4-191.8°C
Elemental Analysis: C23H30N4O4
Calcd. (%): C, 64.76; H, 7.08; N, 13.13
Found (%): C, 64.84; H, 7.30; N, 12.89
IR (KBr) νmax (cm-1):
1695, 1654, 1274, 1107
NMR (CDCl3; 270MHz) δ (ppm):
7.91(1H, d, J=15.8Hz), 7.42(1H, d, J=8.6Hz), 6.98(1H, d, J=15.8Hz), 6.69 (1H, d, J=8.6Hz), 4.11(2H, t, J=7.4Hz), 4.03(3H, s), 4.03-3.95(2H, m), 3.87(3H, s), 3.77(3H, s), 2.19(3H, s), 1.85-1.55(4H, m), 1.03-0.94(6H, m)
Reference Example 13 (E)-1,3-Dipropyl-8-(2,3,4-trimethoxystyryl)xanthine (Compound 20)
Substantially the same procedure as in Reference Example 1 was repeated using 2.00 g (8.85 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.32 g (9.73 mmol) of 2,3,4-trimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from 2-propanol/water to give 1.84 g (yield 49%) of Compound 20 as pale yellow needles.
Melting Point:
246.5-246.8°C
Elemental Analysis: C22H28N4O5
Calcd. (%): C, 61.66; H, 6.58; N, 13.07
Found (%): C, 61.50; H, 6.89; N, 13.06
IR (KBr) νmax (cm-1):
1703, 1651, 1504
NMR (CDCl3; 270MHz) δ (ppm):
12.72(1H, brs), 7.92 (1H, d, J=16.5Hz), 7.31(1H, d, J=8.7Hz), 7.09(1H, d, J=16.5Hz), 6.71(1H, d, J=8.7Hz), 4.25-4.10(4H, m), 3.95(3H, s), 3.91(3H, s), 3.90(3H, s), 2.00-1.65(4H, m), 1.10-0.85(6H, m)
Reference Example 14 (E)-7-Methyl-1,3-dipropyl-8-(2,3,4-trimethoxystyryl)xanthine (Compound 21)
Substantially the same procedure as in Reference Example 1 was repeated using 2.50 g (5.84 mmol) of Compound 20 obtained in Reference Example 13 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol to give 1.70 g (yield 66%) of Compound 21 as yellow needles.
Melting Point:
153.5-153.8°C
Elemental Analysis: C23H30N4O5
Calcd. (%): C, 62.42; H, 6.83; N, 12.66
Found (%): C, 62.77; H, 7.25; N, 12.65
IR (KBr) νmax (cm-1):
1699, 1657, 1590, 1497, 1439
NMR (CDCl3; 270MHz) δ (ppm):
7.88(1H, d, J=15.8Hz), 7.28(1H, d, J=8.9Hz), 7.02(1H, d, J=15.8Hz), 6.71 (1H, d, J=8.9Hz), 4.25-3.95(4H, m), 4.03(3H, s), 3.97(3H, s), 3.91(3H, s), 3.90(3H, s), 2.00-1.65 (4H, m), 1.10-0.85(6H, m)
Reference Example 15 (E)-1,3-Dipropyl-8-(2,4,5-trimethoxystyryl)xanthine (Compound 22)
Substantially the same procedure as in Reference Example 1 was repeated using 2.00 g (8.85 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.32 g (9.73 mmol) of 2,4,5-trimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from 2-propanol/water to give 870 mg (yield 23%) of Compound 22 as a pale yellow powder.
Melting Point:
254.5-255.7°C
Elemental Analysis: C22H28N4O5
Calcd. (%): C, 61.66; H, 6.58; N, 13.07
Found (%): C, 61.94; H, 6.97; N, 13.06
IR (KBr) νmax (cm-1):
1693, 1650, 1517
NMR (CDCl3; 270MHz) δ (ppm):
12.53(1H, brs), 7.97 (1H, d, J=16.5Hz), 7.10(1H, s), 6.99(1H, d, J=16.5Hz), 6.54(1H, s), 4.25-4.10(4H, m), 3.95(3H, s), 3.90(6H, s), 1.90-1.65(4H, m), 1.01(3H, t, J=7.6Hz), 0.86(3H, t, J=7.6Hz)
Reference Example 16 (E)-7-Methyl-1,3-dipropyl-8-(2,4,5-trimethoxystyryl)xanthine (Compound 23)
Substantially the same procedure as in Reference Example 1 was repeated using 0.5 g (1.17 mmol) of Compound 22 obtained in Reference Example 15 in place of Compound B. Then, the resultant crude crystals were recrystallized from toluene/hexane to give 200 mg (yield 39%) of Compound 23 as a pale yellow powder.
Melting Point:
195.5-196.2°C
Elemental Analysis: C23H30N4O5
Calcd. (%): C, 62.42; H, 6.83; N, 12.66
Found (%): C, 62.14; H, 7.12; N, 12.56
IR (KBr) νmax (cm-1):
1688, 1653, 1515, 1439, 1214
NMR (CDCl3; 270MHz) δ (ppm):
7.93(1H, d, J=15.8Hz), 7.05(1H, s), 6.94(1H, d, J=15.8Hz), 6.54(1H, s), 4.15-3.90(4H, m), 4.04(3H, s), 3.95(3H, s), 3.93 (3H, s), 3.91(3H, s), 1.90-1.65(4H, m), 1.03-0.94 (6H, m)
Reference Example 17 (E)-8-(2,4-Dimethoxystyryl)-1,3-dipropylxanthine (Compound 24)
Substantially the same procedure as in Reference Example 1 was repeated using 3.0 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.04 g (14.60 mmol) of 2,4-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.26 g (yield 24%) of Compound 24 as white crystals.
Melting Point:
273.1-273.7°C
Elemental Analysis: C21H26N4O4
Calcd. (%): C, 63.30; H, 6.57; N, 14.06
Found (%): C, 62.94; H, 6.78; N, 14.03
IR (KBr) νmax (cm-1):
1693, 1645, 1506
NMR (DMSO-d6; 270MHz) δ (ppm):
13.39(1H, brs), 7.78 (1H, d, J=16.5Hz), 7.54(1H, d, J=8.2Hz), 6.95(1H, d, J=16.5Hz), 6.63(1H, d, J=2.3Hz), 6.00(1H, dd, J=8.2, 2.3Hz), 4.01-3.85(4H, m), 3.89(3H, s), 3.82 (3H, s), 1.79-1.50(4H, m), 0.93-0.87(6H, m)
Reference Example 18 (E)-8-(2,4-Dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 25)
Substantially the same procedure as in Reference Example 1 was repeated using 600 mg (1.51 mmol) of Compound 24 obtained in Reference Example 17 in place of Compound B. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 556 mg (yield 90%) of Compound 25 as brown needles.
Melting Point:
167.6-167.9°C
Elemental Analysis: C22H28N4O4
Calcd. (%): C, 64.06; H, 6.84; N, 13.58
Found (%): C, 63.98; H, 6.94; N, 13.61
IR (KBr) νmax (cm-1):
1691, 1653, 1603, 1437
NMR (CDCl3; 270MHz) δ (ppm):
7.92(1H, d, J=15.8Hz), 7.48(1H, d, J=8.6Hz), 6.98(1H, d, J=15.8Hz), 6.54 (1H, dd, J=8.6, 2.3Hz), 6.50(1H, d, J=2.3Hz), 4.14-3.95(4H, m), 4.02(3H, s), 3.93(3H, s), 3.86 (3H, s), 1.91-1.65(4H, m), 1.03-0.94(6H, m)
Reference Example 19 (E)-8-(4-Benzyloxy-3,5-dimethoxystyryl)-1,3-dipropylxanthine (Compound 26)
A mixture of 5.0 g (22.3 mmol) of 4-hydroxy-3,5-dimethoxycinnamic acid, 8.0 ml (66.9 mmol) of benzyl bromide, and potassium carbonate was stirred in 50 ml of dimethylformamide at 70°C for 2 hours. Insoluble matters were filtered off and the filtrate was poured into 500 ml of water. The mixture was extracted three times with 100 ml of chloroform. The extract was washed twice with water and twice with a saturated aqueous solution of sodium chloride, and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. To the residue were added 50 ml of an aqueous 2N sodium hydroxide solution and 50 ml of ethanol, followed by heating under reflux for 15 minutes. After cooling, the solution was adjusted to pH 3 with a concentrated hydrochloric acid solution and extracted three times with 50 ml of chloroform. The extract was washed with a saturated aqueous solution of sodium chloride, and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was recrystallized from hexane to give 5.4 g (yield 77%) of (E)-4-benzyloxy-3,5-dimethoxycinnamic acid (Compound G) as pale yellow needles.
Melting Point:
101.8-102.3°C
Elemental Analysis: C18H18O5
Calcd. (%): C, 68.77; H, 5.77
Found (%): C, 68.95; H, 5.79
IR (KBr) νmax (cm-1):
2900(br), 1683, 1630, 1579, 1502, 1281, 1129
NMR (CDCl3; 90MHz) δ (ppm):
7.80(1H, d, J=16Hz), 7.55-7.20(5H, m), 6.80(2H, s), 6.30(1H, d, J=16Hz), 5.08(2H, s)
Substantially the same procedure as in Reference Example 1 was repeated using 3.30 g (14.5 mmol) of 5,6-diamino-1,3-dipropyluracil and 5.0 g (15.9 mmol) of Compound G. Then, the resultant crude crystals were recrystallized from ethanol/2-propanol to give 5.44 g (Yield 74%) of Compound 26 as a white powder.
Melting Point:
221.1-221.4°C
Elemental Analysis: C28H32N4O5
Calcd. (%): C, 66.65; H, 6.39; N, 11.10
Found (%): C, 66.65; H, 6.51; N, 11.01
IR (KBr) νmax (cm-1):
1704, 1637, 1582, 1505
NMR (CDCl3; 90MHz) δ (ppm):
7.69(1H, d, J=16Hz), 7.55-7.20(5H, m), 6.96(1H, d, J=16Hz), 6.80(2H, s), 5.08(2H, s), 4.25-3.95(4H, m), 3.88(6H, s), 2.10-1.65(4H, m), 1.20-0.80(6H, m)
Reference Example 20 (E)-8-(4-Benzyloxy-3,5-dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 27)
Substantially the same procedure as in Reference Example 1 was repeated using 8.20 g (14.5 mmol) of Compound 26 obtained in Reference Example 19 in place of Compound B. Then, the resultant crude crystals were recrystallised from 2-propanol/water to give 4.78 g (yield 64%) of Compound 27 as a white powder.
Melting Point:
164.7-165.1°C
Elemental Analysis: C29H34N4O5
Calcd. (%): C, 67.16; H, 6.60; N, 10.80
Found (%): C, 67.01; H, 6.61; N, 10.70
IR (KBr) νmax (cm-1) :
1695, 1659, 1580, 1542, 1505, 1455, 1335
NMR (CDCl3; 90MHz) δ (ppm):
7.70(1H, d, J=16Hz), 7.55-7.20(5H, m), 6.78(2H, s), 6.72(1H, d, J=16Hz), 5.07(2H, s), 4.25-3.95(4H, m), 4.07(3H, s), 3.89(6H, s), 2.10-1.65(4H, m), 1.20-0.85(6H, m)
Reference Example 21 (E)-8-(2,3-Dimethoxystyryl)-1,3-dipropylxanthine (Compound 28)
Substantially the same procedure as in Reference Example 1 was repeated using 2.0 g (8.85 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.2 g (10.6 mmol) of 2,3-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from chloroform/cyclohexane to give 1.26 g (yield 36%) of Compound 28 as yellow crystals.
Melting Point:
236.0-236.5°C
Elemental Analysis: C21H26N4O4
Calcd. (%): C, 63.30; H, 6.57; N, 14.06
Found (%): C, 62.99; H, 6.71; N, 13.83
IR (KBr) νmax (cm-1):
1701, 1652, 1271
NMR (DMSO-d6; 270MHz) δ (ppm):
13.63 (1H, brs), 7.84 (1H, d, J=16.8Hz), 7.28(1H, d, J=6.8Hz), 7.14-7.05 (3H, m), 4.00(2H, t, J=7.3Hz), 3.88-3.78(2H, m), 3.83(3H, s), 3.79(3H, s), 1.80-1.50(4H, m), 0.93-0.85(6H, m)
Reference Example 22 (E)-8-(2,3-Dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 29)
Substantially the same procedure as in Reference Example 1 was repeated using 1.5 g (3.77 mmol) of Compound 28 obtained in Reference Example 21 in place of Compound B. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 1.22 g (yield 79%) of Compound 29 as pale brown needles.
Melting Point:
163.5-163.7°C
Elemental Analysis: C22H28N4O4
Calcd. (%): C, 64.06; H, 6.84; N, 13.58
Found (%): C, 64.03; H, 7.12; N, 13.42
IR (KBr) νmax (cm-1):
1695, 1657, 1272
NMR (DMSO-d6; 270MHz) δ (ppm):
7.88(1H, d, J=15.8Hz), 7.50(1H, dd, J=1.7, 7.6Hz), 7.32(1H, d, J=15.8Hz), 7.17-7.06(2H, m), 4.02(3H, s), 4.02-3.98(2H, m), 3.86-3.81(2H, m), 3.84(3H, s), 3.79(3H, s), 1.80-1.65(2H, m), 1.65-1.50(2H, m), 0.93-0.84(6H, m)
Reference Example 23 (E)-8-(3,4-Dimethylstyryl)-1,3-dipropylxanthine (Compound 30)
Substantially the same procedure as in Reference Example 1 was repeated using 5.90 g (26.0 mmol) of 5,6-diamino-1,3-dipropyluracil and 5.5 g (31.3 mmol) of 3,4-dimethylcinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 7.70 g (yield 81%) of Compound 30 as a white powder.
Melting Point:
252.7-254.0°C
Elemental Analysis: C21H26N4O2
Calcd. (%): C, 68.83; H, 7.15; N, 15.29
Found (%): C, 68.43; H, 7.22; N, 15.22
IR (KBr) νmax (cm-1):
1700, 1648, 1490
NMR (DMSO-d6; 270MHz) δ (ppm):
7.40(1H, d, J=16.2Hz), 7.37(1H, s), 7.29(1H, d, J=7.2Hz), 7.14(1H, d, J=7.2Hz), 6.95(1H, d, J=16.2Hz), 3.95(2H, t, J=7.2Hz), 3.83(2H, t, J=7.4Hz), 2.25(3H, s), 2.23 (3H, s), 1.80-1.55(4H, m), 1.00-0.90(6H, m)
Reference Example 24 (E)-8-(3,4-Dimethylstyryl)-7-methyl-1,3-dipropylxanthine (Compound 31)
Substantially the same procedure as in Reference Example 1 was repeated using 6.50 g (17.8 mmol) of Compound 30 obtained in Reference Example 23 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol/water to give 5.62 g (yield 83%) of Compound 31 as white needles.
Melting Point:
169.3-170.3°C
Elemental Analysis: C22H28N4O2
Calcd. (%): C, 69.45; H, 7.42; N, 14.72
Found (%): C, 69.33; H, 7.42; N, 14.86
IR (KBr) νmax (cm-1):
1693, 1656
NMR (DMSO-d6; 270MHz) δ (ppm):
7.59(1H, d, J=15.8Hz), 7.58(1H, s), 7.49(1H, d, J=7.6Hz), 7.26(1H, d, J=15.8Hz), 7.19(1H, d, J=7.6Hz), 4.02(3H, s), 4.05-3.90(2H, m), 3.84(2H, t, J=7.4Hz), 2.27(3H, s), 2.25(3H, s), 1.85-1.50(4H, m), 1.00-0.85(6H, m)
Reference Example 25
(E)-8-(3,5-Dimethoxystyryl)-1,3-dipropylxanthine (Compound 32)
Substantially the same procedure as in Reference Example 1 was repeated using 3.95 g (17.5 mmol) of 5,6-diamino-1,3-dipropyluracil and 4.0 g (19.2 mmol) of 3,5-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylformamide/water to give 3.78 g (yield 54%) of Compound 32 as a white powder.
Melting Point:
248.7-250.3°C
Elemental Analysis: C21H26N4O4
Calcd. (%): C, 63.30; H, 6.58; N, 14.06
Found (%): C, 63.02; H, 6.71; N, 14.06
IR (KBr) νmax (cm-1):
1687, 1631, 1588, 1494
NMR (DMSO-d6; 270MHz) δ (ppm):
7.56(1H, d, J=16.6Hz), 7.08(1H, d, J=16.6Hz), 6.78(2H, d, J=2.0Hz), 6.50 (1H, t, J=2.0Hz), 3.98(2H, t, J=7.3Hz), 3.85(2H, t, J=7.3Hz), 3.79(6H, s), 1.80-1.50(4H, m), 0.92-0.84(6H, m)
Reference Example 26 (E)-8-(3,5-Dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 33)
Substantially the same procedure as in Reference Example 1 was repeated using 3.23 g (8.27 mmol) of Compound 32 obtained in Reference Example 25 in place of Compound B. Then, the resultant crude crystals were recrystallized from acetonitrile to give 2.96 g (yield 87%) of Compound 33 as white needles.
Melting Point:
178.0-178.2°C
Elemental Analysis: C22H28N4O4
Calcd. (%): C, 64.06; H, 6.84; N, 13.58
Found (%): C, 63.87; H, 7.11; N, 13.66
IR (KBr) νmax (cm-1):
1692, 1657, 1592
NMR (DMSO-d6; 270MHz) δ (ppm):
7.59(1H, d, J=15.9Hz), 7.35(1H, d, J=15.9Hz), 6.98(2H, d, J=2.9Hz), 6.51 (1H, t, J=2.9Hz), 4.04(3H, s), 4.10-3.95(2H, m), 3.90-3.75(2H, m), 3.80(6H, s), 1.80-1.50(4H, m), 1.00-0.80(6H, m)
Reference Example 27 (E)-8-(3-Nitrostyryl)-1,3-dipropylxanthine (Compound 34)
Substantially the same procedure as in Reference Example 1 was repeated using 4.0 g (17.7 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.8 g (19.5 mmol) of 3-nitrocinnamic acid. Then, the resultant crude crystals were recrystallized from toluene to give 3.86 g (yield 57%) of Compound 34 as pale yellow needles.
Melting Point:
256.5-256.8°C
Elemental Analysis: C19H21N5O4·0.25C6H5CH3
Calcd. (%): C, 61.32; H, 5.70; N, 17.23
Found (%): C, 61.64; H, 5.94; N, 17.29
IR (KBr) νmax (cm-1):
1701, 1649, 1529, 1355
NMR (DMSO-d6; 270MHz) δ (ppm):
8.42(1H, s), 8.19(1H, d, J=8.0Hz), 8.12(1H, d, J=7.6Hz), 7.80-7.65(2H, m), 7.25(1H, d, J=16.5Hz), 4.00(2H, t, J=7.2Hz), 3.86(2H, t, J=7.3Hz), 1.80-1.55(4H, m), 1.00-0.80(6H, m)
Reference Example 28 (E)-7-Methyl-8-(3-nitrostyryl)-1,3-dipropylxanthine (Compound 35)
Substantially the same procedure as in Reference Example 1 was repeated using 3.20 g (8.36 mmol) of Compound 34 obtained in Reference Example 27 in place of Compound B. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 2.41 g (yield 73%) of Compound 35 as yellow needles.
Melting Point:
218.2-218.4°C
Elemental Analysis: C20H23N5O4
Calcd. (%): C, 60.44; H, 5.83; N, 17.62
Found (%): C, 59.94; H, 5.97; N, 17.43
IR (KBr) νmax (cm-1):
1699, 1662, 1521
NMR (DMSO-d6; 270MHz) δ (ppm):
8.70(1H, m), 8.24(1H, d, J=7.9Hz), 8.19(1H, dd, J=1.6, 7.6Hz), 7.78(1H, d, J=15.9Hz), 7.71(1H, t, J=7.9Hz), 7.61(1H, d, J=15.9Hz), 4.08(3H, s), 4.01(2H, t, J=7.3Hz), 3.85 (2H, t, J=7.3Hz), 1.85-1.55(4H, m), 0.91(3H, t, J=7.5Hz), 0.87(3H, t, J=7.4Hz)
Reference Example 29 (E)-8-(3-Fluorostyryl)-1,3-dipropylxanthine (Compound 36)
Substantially the same procedure as in Reference Example 1 was repeated using 3.95 g (17.5 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.19 g (19.2 mmol) of 3-fluorocinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylformamide/water to give 4.67 g (yield 75%) of Compound 36 as a pale yellow powder.
Melting Point:
265.0-265.9°C
Elemental Analysis: C19H21N4O2F
Calcd. (%): C, 64.03; H, 5.94; N, 15.72
Found (%): C, 64.02; H, 5.96; N, 15.46
IR (KBr) νmax (cm-1):
1701, 1646
NMR (DMSO-d6; 270MHz) δ (ppm):
7.63(1H, d, J=16.3Hz), 7.53-7.41(3H, m), 7.23-7.15(1H, m), 7.12(1H, d, J=16.3Hz), 3.99(2H, t, J=7.0Hz), 3.86(2H, t, J=7.3Hz), 1.80-1.50(4H, m), 0.93-0.85(6H, m)
Reference Example 30 (E)-8-(3-Fluorostyryl)-7-methyl-1,3-dipropylxanthine (Compound 37)
Substantially the same procedure as in Reference Example 1 was repeated using 2.92 g (8.19 mmol) of Compound 36 obtained in Reference Example 29 in place of Compound B. Then, the resultant crude crystals were recrystallized from toluene/cyclohexane to give 2.67 g (yield 88%) of Compound 37 as pale yellow needles.
Melting Point:
161.9-162.0°C
Elemental Analysis: C20H23N4O2F
Calcd. (%): C, 64.85; H, 6.26; N, 15.12
Found (%): C, 64.61; H, 6.40; N, 14.86
IR (KBr) νmax (cm-1):
1693, 1656, 1544
NMR (DMSO-d6; 270MHz) δ (ppm):
7.80-7.60(3H, m), 7.50-7.38(2H, m), 7.19(1H, dt, J=2.3, 8.3Hz), 4.04(3H, s), 4.00(2H, t, J=7.3Hz), 3.84(2H, t, J=7.5Hz), 1.80-1.55 (4H, m), 1.00-0.80 (6H, m)
Reference Example 31 (E)-8-(3-Chlorostyryl)-1,3-dipropylxanthine (Compound 38)
Substantially the same procedure as in Reference Example 1 was repeated using 3.95 g (17.5 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.51 g (19.2 mmol) of 3-chlorocinnamic acid. Then, the resultant crude crystals were recrystallized from dimethylformamide/water to give 4.44 g (yield 67%) of Compound 38 as pale yellow crystals.
Melting Point:
258.9-259.4°C
Elemental Analysis: C19H21N4O2Cl
Calcd. (%): C, 61.21; H, 5.68; N, 15.03
Found (%): C, 61.52; H, 5.73; N, 14.79
IR (KBr) νmax (cm-1):
1700, 1644, 1588, 1494
NMR (DMSO-d6; 270MHz) δ (ppm):
13.7(1H, brs), 7.71-7.52(3H, m), 7.48-7.39(2H, m), 7.12(1H, d, J=16.3Hz), 3.99(2H, t, J=7.0Hz), 3.86(2H, t, J=7.0Hz), 1.80-1.50(4H, m), 0.93-0.84(6H, m)
Reference Example 32 (E)-8-(3-Chlorostyryl)-7-methyl-1,3-dipropylxanthine (Compound 39)
Substantially the same procedure as in Reference Example 1 was repeated using 2.85 g (7.66 mmol) of Compound 38 obtained in Reference Example 31 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol to give 2.69 g (yield 91%) of Compound 39 as white needles.
Melting Point:
167.7-167.9°C
Elemental Analysis: C20H23N4O2Cl
Calcd. (%): C, 62.09; H, 5.99; N, 14.48
Found (%): C, 62.00; H, 6.08; N, 14.27
IR (KBr) νmax (cm-1):
1691, 1657, 1543
NMR (DMSO-d6; 270MHz) δ (ppm):
7.99(1H, s), 7.72 (1H, d, J=6.6Hz), 7.63(1H, d, J=15.8Hz), 7.50-7.30(3H, m), 4.05(3H, s), 4.00(2H, t, J=7.5Hz), 3.84(2H, t, J=7.4Hz), 1.80-1.55(4H, m), 1.00-0.80(6H, m)
Reference Example 33 (E)-8-(2-Chlorostyryl)-1,3-dipropylxanthine (Compound 40)
Substantially the same procedure as in Reference Example 1 was repeated using 3.00 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.67 g (14.6 mmol) of 2-chlorocinnamic acid. Then, the resultant crude crystals were recrystallized from toluene to give 3.72 g (yield 82%) of Compound 40 as white needles.
Melting Point:
269.4-269.9°C
Elemental Analysis: C19H21N4O2Cl
Calcd. (%): C, 61.21; H, 5.68; N, 15.03
Found (%): C, 60.94; H, 5.69; N, 14.68
IR (KBr) νmax (cm-1):
1695, 1645, 1493
NMR (DMSO-d6; 270MHz) δ (ppm):
8.00-7.80(2H, m), 7.55-7.50(1H, m), 7.45-7.37(2H, m), 7.12(1H, d, J=16.5Hz), 3.99(2H, t, J=7.3Hz), 3.86(2H, t, J=7.4Hz), 1.80-1.55(4H, m), 1.00-0.80(6H, m)
Reference Example 34 (E)-8-(2-Chlorostyryl)-7-methyl-1,3-dipropylxanthine (Compound 41)
Substantially the same procedure as in Reference Example 1 was repeated using 2.37 g (6.37 mml) of Compound 40 obtained in Reference Example 33 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol/water to give 1.88 g (yield 77%) of Compound 41 as yellow needles.
Melting Point:
159.0-159.9°C
Elemental Analysis: C20H23N4O2Cl
Calcd. (%): C, 62.09; H, 5.99; N, 14.48
Found (%): C, 61.75; H, 6.14; N, 14.45
IR (KBr) νmax (cm-1):
1696, 1650, 1544
NMR (DMSO-d6; 270MHz) δ (ppm):
8.10(1H, dd, J=2.3, 7.3Hz), 7.97(1H, d, J=15.5Hz), 7.55-7.50(1H, m), 7.46-7.35(3H, m), 4.05(3H, s), 4.00(2H, t, J=7.3Hz), 3.84 (2H, t, J=7.3Hz), 1.80-1.55 (4H, m), 1.00-0.80(6H, m)
Reference Example 35 (E)-8-(2-Fluorostyryl)-1,3-dipropylxanthine (Compound 42)
Substantially the same procedure as in Reference Example 1 was repeated using 3.00 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.43 g (14.6 mmol) of 2-fluorocinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 3.23 g (yield 68%) of Compound 42 as white needles.
Melting Point:
258.8-259.2°C
Elemental Analysis: C19H21N4O2F
Calcd. (%): C, 64.03; H, 5.94; N, 15.72
Found (%): C, 64.01; H, 6.11; N, 15.52
IR (KBr) νmax (cm-1):
1702, 1648
NMR (DMSO-d6; 270MHz) δ (ppm):
7.85-7.77(2H, m), 7.46-7.32(1H, m), 7.29-7.23(2H, m), 7.16(1H, d, J=16.5Hz), 3.99(2H, t, J=7.1Hz), 3.86(2H, t, J=7.3Hz), 1.80-1.55(4H, m), 1.00-0.80(6H, m)
Reference Example 36 (E)-8-(2-Fluorostyryl)-7-methyl-1,3-dipropylxanthine (Compound 43)
Substantially the same procedure as in Reference Example 1 was repeated using 3.50 g (9.83 mmol) of Compound 42 obtained in Reference Example 35 in place of Compound B. Then, the resultant crude crystals were recrystallized from ethanol/water to give 1.23 g (yield 34%) of Compound 43 as white needles.
Melting Point:
155.5-155.9°C
Elemental Analysis: C20H23N4O2F
Calcd. (%): C, 64.85; H, 6.26; N, 15.12
Found (%): C, 65.00; H, 6.44; N, 15.34
IR (KBr) νmax (cm-1):
1694, 1660
NMR (DMSO-d6; 270MHz) δ (ppm):
8.02(1H, t, J=8.3Hz), 7.75(1H, d, J=15.5Hz), 7.47-7.40(2H, m), 7.40-7.25(2H, m), 4.03(3H, s), 4.00(2H, t, J=7.4Hz), 3.84(2H, t, J=7.4Hz), 1.80-1.55(4H, m), 1.00-0.80(6H, m)
Reference Example 37 (E)-8-(4-Methoxy-2,5-dimethylstyryl)-1,3-dipropylxanthine (Compound 44)
Substantially the same procedure as in Reference Example 1 was repeated using 2.5 g (11.1 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.51 g (12.17 mmol) of 4-methoxy-2,5-dimethylcinnamic acid. Then, the resultant crude crystals were recrystallized from ethanol/water to give 1.98 g (yield 45%) of Compound 44 as white crystals.
Melting Point:
268.0-269.2°C
Elemental Analysis: C22H28N4O3
Calcd. (%): C, 66.65; H, 7.11; N, 14.13
Found (%): C, 66.82; H, 7.34; N, 14.14
IR (KBr) νmax (cm-1):
1694, 1644, 1506, 1261
NMR (DMSO-d6; 270MHz) δ (ppm):
12.95(1H, brs), 7.95 (1H, d, J=15.8Hz), 7.42(1H, s), 6.89(1H, d, J=15.8Hz), 6.66(1H, s), 4.19-4.07(4H, m), 3.86(3H, s), 2.48(3H, s), 2.21(3H, s), 1.91-1.74(4H, m), 1.02(3H, t, J=6.9Hz), 0.93(3H, t, J=6.9Hz)
Reference Example 38 (E)-8-(4-Methoxy-2,5-dimethylstyryl)-7-methyl-1,3-dipropylxanthine (Compound 45)
Substantially the same procedure as in Reference Example 1 was repeated using 973 mg (2.45 mmol) of Compound 44 obtained in Reference Example 37 in place of Compound B. Then, the resultant crude crystals were recrystallized from 2-propanol/water to give 966 mg (yield 96%) of Compound 45 as pale yellow needles.
Melting Point:
245.3-246.3°C
Elemental Analysis: C23H30N4O3
Calcd. (%): C, 67.30; H, 7.36; N, 13.65
Found (%): C, 67.37; H, 7.51; N, 13.69
IR (KBr) νmax (cm-1):
1690, 1655, 1508, 1261
NMR (DMSO-d6; 270MHz) δ (ppm):
7.96(1H, d, J=15.8Hz), 7.41(1H, s), 6.70(1H, d, J=15.8Hz), 6.66(1H, s), 4.14-4.09(2H, m), 4.05(3H, s), 4.01-3.95(2H, m), 2.48(3H, s), 2.22(3H, s), 1.91-1.77(2H, m), 1.74-1.63(2H, m), 1.03-0.94(6H, m)
Reference Example 39 (Z)-8-(3,4-Dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 46) (an about 6 : 4 mixture of Compound 46 and Compound 1)
Compound 1 (2.00 g, 4.85 mmol) obtained in Reference Example 1 was dissolved in 180 ml of chloroform, and the solution was irradiated with sunlight for 24 hours. After careful concentration of the reaction mixture, methanol was added thereto and deposited crystals were collected by filtration. The crystals were dried under reduced pressure to give 1.72 g (yield 86%) of a mixture of Compound 46 and Compound 1 as a pale yellow powder (The ratio of Compound 46 to Compound 1 was about 6 : 4 by NMR analysis).
Melting Point:
115.2-119.4°C
Elemental Analysis: C22H28N4O4
Calcd. (%): C, 64.06; H, 6.84; N, 13.58
Found (%): C, 64.02; H, 6.82; N, 13.46
IR (KBr) νmax (cm-1):
1695, 1656, 1521
NMR (DMSO-d6; 270MHz) δ (ppm):
7.60(1x4/10H, d, J=15.8Hz), 7.40(1x4/10H, d, J=2.0Hz), 7.32-7.17 (2x4/10H + 2x6/10H, m), 6.99(1x4/10H, d, J=8.4Hz), 6.94(1x6/10H, d, J=12.7Hz), 6.92(1x6/10H, d, J=8.2Hz), 6.39(1x6/10H, d, J=12.7Hz), 4.02 (3x4/10H, s), 4.10-3.80(4H, m), 3.85(3x4/10H, s), 3.80(3x4/10H, s), 3.77(6x6/10H, s), 3.64(3x6/10H, s), 1.80-1.55(4H, m), 1.00-0.85(6H, m)
Reference Example 40 (E)-8-(4-Ethoxystyryl)-1,3-dipropylxanthine (Compound 47)
Substantially the same procedure as in Reference Example 1 was repeated using 3.0 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.80 g (14.6 mmol) of 4-ethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 3.57 g (yield 70%) of Compound 47 as pale yellow needles.
Melting Point:
261.6-262.0°C
Elemental Analysis: C21H26N4O3
Calcd. (%): C, 65.96; H, 6.85; N, 14.65
Found (%): C, 65.93; H, 7.13; N, 14.65
IR (KBr) νmax (cm-1):
1701, 1635, 1516, 1261
NMR (DMSO-d6; 270MHz) δ (ppm):
13.37(1H, brs), 7.59 (1H, d, J=16.5Hz), 7.55(2H, d, J=8.6Hz), 6.96(2H, d, J=8.6Hz), 6.88(1H, d, J=16.5Hz), 4.07(2H, q, J=6.9Hz), 3.99(2H, t, J=7.3Hz), 3.86(2H, t, J=7.3Hz), 1.73(2H, m), 1.58(2H, m), 1.34(3H, t, J=6.9Hz), 0.90(3H, t, J=7.3Hz); 0.87(3H, t, J=7.3Hz)
Reference Example 41 (E)-8-(4-Ethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 48)
Substantially the same procedure as in Reference Example 1 was repeated using 2.0 g (5.23 mmol) of Compound 47 obtained in Reference Example 40 in place of Compound B. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 1.72 g (yield 83%) of Compound 48 as pale green needles.
Melting Point:
174.7-175.0°C
Elemental Analysis: C22H28N4O3
Calcd. (%): C, 66.65; H, 7.11; N, 14.13
Found (%): C, 66.60; H, 7.20; N, 14.27
IR (KBr) νmax (cm-1):
1702, 1660, 1515, 1252
NMR (CDCl3; 270MHz) δ (ppm):
7.74(1H, d, J=15.8Hz), 7.52(2H, d, J=8.6Hz), 6.92(2H, d, J=8.6Hz), 6.76 (1H, d, J=15.8Hz), 4.09(2H, t, J=7.6Hz), 4.08(2H, q, J=6.9Hz), 4.04(3H, s), 3.99(2H, t, J=7.6Hz), 1.44(3H, t, J=6.9Hz), 1.00(3H, t, J=7.6Hz), 0.97 (3H, t, J=7.6Hz)
Reference Example 42 (E)-8-(4-Propoxystyryl)-1,3-dipropylxanthine (Compound 49)
Substantially the same procedure as in Reference Example 1 was repeated using 3.0 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.01 g (14.6 mmol) of 4-propoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 1.71 g (yield 33%) of Compound 49 as pale brown needles.
Melting Point:
248.3-248.7°C
Elemental Analysis: C22H28N4O3
Calcd. (%): C, 66.65; H, 7.11; N, 14.13
Found (%): C, 66.50; H, 7.48; N, 14.25
IR (KBr) νmax (cm-1):
1694, 1649, 1514, 1253
NMR (DMSO-d6; 270MHz) δ (ppm):
13.34(1H, brs), 7.58 (1H, d, J=16.5Hz), 7.55(2H, d, J=8.6Hz), 6.99(2H, d, J=8.6Hz), 6.88(1H, d, J=16.5Hz), 4.01-3.95(4H, m), 3.86(2H, t, J=7.3Hz), 1.78-1.70(4H, m), 1.62-1.54(2H, m), 0.98(3H, t, J=7.3Hz), 0.90(3H, t, J=7.6Hz), 0.87(3H, t, J=7.6Hz)
Reference Example 43 (E)-7-Methyl-8-(4-propoxystyryl)-1,3-dipropylxanthine (Compound 50)
Substantially the same procedure as in Reference Example 1 was repeated using 1.0 g (2.52 mmol) of Compound 49 obtained in Reference Example 42 in place of Compound B. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 863 mg (yield 83%) of Compound 50 as pale yellow needles.
Melting Point:
172.6-173.5°C
Elemental Analysis: C23H30N4O3
Calcd. (%): C, 67.30; H, 7.36; N, 13.65
Found (%): C, 67.15; H, 7.65; N, 13.58
IR (KBr) νmax (cm-1):
1699, 1658, 1514, 1252
NMR (CDCl3; 270MHz) δ (ppm):
7.74(1H, d, J=15.8Hz), 7.52(2H, d, J=8.9Hz), 6.92(2H, d, J=8.9Hz), 6.76 (1H, d, J=15.8Hz), 4.13-3.94(6H, m), 4.04(3H, s), 1.90-1.62 (6H, m), 1.08-0.94 (9H, m)
Reference Example 44 (E)-8-(4-Butoxystyryl)-1,3-dipropylxanthine (Compound 51)
Substantially the same procedure as in Reference Example 1 was repeated using 3.0 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.21 g (14.6 mmol) of 4-butoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 3.47 g (yield 64%) of Compound 51 as white needles.
Melting Point:
237.3-238.9°C
Elemental Analysis: C23H30N4O3
Calcd. (%): C, 67.30; H, 7.36; N, 13.65
Found (%): C, 67.39; H, 7.45; N, 13.59
IR (KBr) νmax (cm-1):
1697, 1644, 1514, 1257
NMR (DMSO-d6; 270MHz) δ (ppm):
13.37(1H, brs), 7.58 (1H, d, J=16.2Hz), 7.55 (2H, d, J=8.6Hz), 6.97 (2H, d, J=8.6Hz), 6.88 (1H, d, J=16.2Hz), 4.04-3.96 (4H, m), 3.86(2H, t, J=7.3Hz), 1.80-1.37(8H, m), 0.97-0.84 (9H, m)
Reference Example 45 (E)-8-(4-Butoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 52)
Substantially the same procedure as in Reference Example 1 was repeated using 2.0 g (4.87 mmol) of Compound 51 obtained in Reference Example 44 in place of Compound B. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 1.56 g (yield 75%) of Compound 52 as pale green needles.
Melting Point:
134.8-135.6°C
Elemental Analysis: C24H32N4O3
Calcd. (%): C, 67.90; H, 7.59; N, 13.20
Found (%): C, 68.22; H, 7.88; N, 13.49
IR (KBr) νmax (cm-1):
1696, 1651, 1513, 1247
NMR (CDCl3; 270MHz) δ (ppm):
7.74(1H, d, J=15.5Hz), 7.52(2H, d, J=8.6Hz), 6.92(2H, d, J=8.6Hz), 6.76 (1H, d, J=15.5Hz), 4.13-3.95(6H, m), 4.04(3H, s), 1.88-1.44 (8H, m), 1.03-0.94 (9H, m)
Reference Example 46 (E)-8-(3,4-Dihydroxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 53)
Compound 1 (770 mg, 1.87 mmol) obtained in Reference Example 1 was dissolved in 15 ml of methylene chloride. To the solution was added 5.6 ml (5.6 mmol) of boron tribromide (1.0M methylene chloride solution) under ice cooling in argon atmosphere, and the mixture was stirred overnight at room temperature. Methanol was added thereto and the mixture was separated with chloroform-an aqueous solution of sodium bicarbonate. The organic layer was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography to give 550 mg (yield 77%) of Compound 53 as a yellow solid, which was then triturated with ether to give a yellow powder.
Melting Point:
250.1-251.4°C
Elemental Analysis: C20H24N4O4
Calcd. (%): C, 62.49; H, 6.29; N, 14.57
Found (%): C, 62.27; H, 6.48; N, 14.74
IR (KBr) νmax (cm-1):
1680, 1640, 1543, 1306
NMR (DMSO-d6; 270MHz) δ (ppm):
9.31(1H, brs), 8.95(1H, brs), 7.49(1H, d, J=15.8Hz), 7.15(1H, d, J=2.0Hz), 7.04(1H, dd, J=7.9, 2.0Hz), 6.98(1H, d, J=15.8Hz), 6.78(1H, d, J=7.9Hz), 3.99(2H, t, J=7.6Hz), 3.98 (3H, s), 3.84(2H, t, J=7.4Hz), 1.73(2H, m), 1.57 (2H, m), 0.90(3H, t, J=7.4Hz), 0.87(3H, t, J=7.4Hz)
Reference Example 47 (E)-8-(3,4-Diethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 54)
Compound 53 (390 mg, 1.01 mmol) obtained in Reference Example 46 was dissolved in 10 ml of dimethylformamide. To the solution were added 0.20 ml (2.50 mmol) of ethyl iodide and 420 mg (3.04 mmol) of potassium carbonate, and the mixture was stirred overnight at room temperature. Water was added thereto to dissolve potassium carbonate and deposited crystals were collected by filtration. The collected crude crystals were recrystallized from hexane/ethyl acetate to give 237 mg (yield 53%) of Compound 54 as pale yellow needles.
Melting Point:
173.8-174.0°C
Elemental Analysis: C24H32N4O4
Calcd. (%): C, 65.44; H, 7.32; N, 12.72
Found (%): C, 65.42; H, 7.48; N, 12.62
IR (KBr) νmax (cm-1):
1694, 1653, 1508, 1268
NMR (CDCl3; 270MHz) δ (ppm):
7.71(1H, d, J=15.5Hz), 7.15(1H, dd, J=8.3, 2.0Hz), 7.10(1H, d, J=2.0Hz), 6.89(1H, d, J=8.3Hz), 6.74(1H, d, J=15.5Hz), 4.16 (2H, q, J=6.9Hz), 4.14(2H, q, J=6.9Hz), 4.08-3.95 (4H, m), 4.05(3H, s), 1.91-1.76(2H, m), 1.76-1.62 (2H, m), 1.49(3H, t, J=6.9Hz), 1.48(3H, t, J=6.9Hz), 1.00(3H, t, J=7.6Hz), 0.97(3H, t, J=7.6Hz)
Reference Example 48 (E)-8-(3-Bromo-4-methoxystyryl)-1,3-dipropylxanthine (Compound 55)
Substantially the same procedure as in Reference Example 1 was repeated using 3.0 g (13.3 mmol) of 5,6-diamino-1,3-dipropyluracil and 3.75 g (14.6 mmol) of 3-bromo-4-methoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 3.43 g (yield 58%) of Compound 55 as yellow needles.
Melting Point:
279.8-280.6°C
Elemental Analysis: C20H23N4O3Br
Calcd. (%): C, 53.70; H, 5.18; N, 12.52
Found (%): C, 53.77; H, 5.20; N, 12.49
IR (KBr) νmax (cm-1):
1685, 1633, 1599, 1503, 1279
NMR (DMSO-d6; 270MHz) δ (ppm):
13.42(1H, brs), 7.85 (1H, d, J=2.0Hz), 7.61(1H, dd, J=8.4, 2.0Hz), 7.55 (1H, d, J=16.3Hz), 7.15(1H, d, J=8.4Hz), 6.94(1H, d, J=16.3Hz), 3.98(2H, t, J=7.4Hz), 3.89(3H, s), 3.86(2H, t, J=7.4Hz), 1.80-1.52(4H, m), 0.89(6H, q, J=7.4Hz)
Reference Example 49 (E)-8-(3-Bromo-4-methoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 56)
Substantially the same procedure as in Reference Example 1 was repeated using 750 mg (1.68 mmol) of Compound 55 obtained in Reference Example 48 in place of Compound B. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 588 mg (yield 76%) of Compound 56 as pale yellow needles.
Melting Point:
209.4-210.8°C
Elemental Analysis: C21H25N4O3Br
Calcd. (%): C, 54.67; H, 5.46; N, 12.14
Found (%): C, 54.47; H, 5.51; N, 11.91
IR (KBr) νmax (cm-1):
1693, 1656, 1542, 1500, 1264
NMR (CDCl3; 270MHz) δ (ppm):
7.83(1H, d, J=2.0Hz), 7.68(1H, d, J=15.8Hz), 7.48(1H, dd, J=8.4, 2.0Hz), 6.92(1H, d, J=8.4Hz), 6.78(1H, d, J=15.8Hz), 4.13-4.07(2H, m), 4.06(3H, s), 4.01-3.97(2H, m), 3.95 (3H, s), 1.90-1.65(4H, m), 1.00(3H, t, J=7.4Hz), 0.97(3H, t, J=7.4Hz)
Reference Example 50 (E)-8-(2-Bromo-4,5-dimethoxystyryl)-1,3-dipropylxanthine (Compound 57)
Substantially the same procedure as in Reference Example 1 was repeated using 2.0 g (8.85 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.80 g (9.75 mmol) of 2-bromo-4,5-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane to give 2.38 g (yield 56%) of Compound 57 as pale yellow needles.
Melting Point:
248.2-249.5°C
Elemental Analysis: C21H25N4O4Br
Calcd. (%): C, 52.84; H, 5.28; N, 11.74
Found (%): C, 52.73; H, 5.31; N, 11.45
IR (KBr) νmax (cm-1):
1697, 1643, 1506, 1263
NMR (DMSO-d6; 270MHz) δ (ppm):
13.75(1H, brs), 7.81 (1H, d, J=16.3Hz), 7.39(1H, s), 7.20(1H, s), 7.09 (1H, d, J=16.3Hz), 4.00-3.82(4H, m), 3.86(3H, s), 3.82(3H, s), 1.76-1.54(4H, m), 0.92-0.85(6H, m)
Reference Example 51 (E)-8-(2-Bromo-4,5-dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 58)
Substantially the same procedure as in Reference Example 1 was repeated using 800 mg (1.68 mmol) of Compound 57 obtained in Reference Example 50 in place of Compound B. Then, the resultant crude crystals were recrystallized from dioxane to give 766 mg (yield 93%) of Compound 58 as yellow needles.
Melting Point:
228.8-229.4°C
Elemental Analysis: C22H27N4O4Br
Calcd. (%): C, 53.78; H, 5.54; N, 11.40
Found (%): C, 53.76; H, 5.67; N, 11.16
IR (KBr) νmax (cm-1):
1688, 1650, 1509, 1266
NMR (CDCl3; 270MHz) δ (ppm):
8.01(1H, d, J=15.8Hz), 7.11(1H, s), 7.09(1H, s), 6.75(1H, d, J=15.8Hz), 4.15-3.92(4H, m), 4.08(3H, s), 3.95(3H, s), 3.92 (3H, s), 1.91-1.77(2H, m), 1.74-1.63(2H, m), 1.03-0.94 (6H, m)
Reference Example 52 (E)-8-(3-Bromo-4,5-dimethoxystyryl)-1,3-dipropylxanthine (Compound 59)
Substantially the same procedure as in Reference Example 1 was repeated using 1.5 g (6.64 mmol) of 5,6-diamino-1,3-dipropyluracil and 2.10 g (7.31 mmol) of 3-bromo-4,5-dimethoxycinnamic acid. Then, the resultant crude crystals were recrystallized from dioxane/water to give 2.11 g (yield 67%) of Compound 59 as white needles.
Melting Point:
276.7-277.5°C
Elemental Analysis: C21H25N4O4Br
Calcd. (%): C, 52.84; H, 5.28; N, 11.74
Found (%): C, 52.72; H, 5.16; N, 11.56
IR (KBr) νmax (cm-1):
1701, 1650, 1562, 1498
NMR (DMSO-d6; 270MHz) δ (ppm):
13.44(1H, brs), 7.55 (1H, d, J=16.3Hz), 7.39(1H, d, J=2.0Hz), 7.36(1H, d, J=2.0Hz), 7.07(1H, d, J=16.3Hz), 3.99(2H, t, J=7.4Hz), 3.91(3H, s), 3.86(2H, t, J=7.4Hz), 3.78 (3H, s), 1.77-1.52(4H, m), 0.93-0.85(6H, m)
Reference Example 53 (E)-8-(3-Bromo-4,5-dimethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 60)
Substantially the same procedure as in Reference Example 1 was repeated using 1.0 g (2.10 mmol) of Compound 59 obtained in Reference Example 52 in place of Compound B. Then, the resultant crude crystals were recrystallized from hexane/ethyl acetate to give 952 mg (yield 93%) of Compound 60 as pale yellow needles.
Melting Point:
180.9-181.6°C
MS-EI m/e:
490, 492
IR (KBr) νmax (cm-1):
1691, 1648, 1542, 1493
NMR (CDCl3; 270MHz) δ (ppm):
7.68(1H, d, J=15.8Hz), 7.42(1H, d, J=2.0Hz), 7.02(1H, d, J=2.0Hz), 6.80 (1H, d, J=15.8Hz), 4.13-3.95(4H, m), 4.08(3H, s), 3.94(3H, s), 3.90(3H, s), 1.90-1.65(4H, m), 1.01 (3H, t, J=7.4Hz), 0.97(3H, t, J=7.4Hz)
Reference Example 54 (E)-8-(3-Hydroxy-4-methoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 63)
Compound 53 (500 mg, 1.30 mmol) obtained in Reference Example 46 was dissolved in 10 ml of dimethylformamide. To the solution were added 0.40 ml (6.43 mmol) of methyl iodide and 400 mg (6.50 mmol) of lithium carbonate, and the mixture was stirred at 80°C for 5 hours. Water was added thereto to dissolve lithium carbonate and deposited crystals were collected by filtration. The collected crude crystals were dissolved in chloroform, washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, followed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (eluent: chloroform) to give 162 mg (yield 31%) of Compound 63 as yellow grains.
Melting Point:
200.3-203.6°C
IR (KBr) νmax (cm-1):
1683, 1642, 1512, 1278
NMR (DMSO-d6; 270MHz) δ (ppm):
8.98(1H, brs), 7.52(1H, d, J=15.5Hz), 7.22(1H, d, J=2.0Hz), 7.15(1H, dd, J=8.3, 2.0Hz), 7.06(1H, d, J=15.5Hz), 6.96 (1H, d, J=8.3Hz), 4.02-3.97(2H, m), 4.00(3H, s), 3.84-3.82 (2H, m), 3.82(3H, s), 1.80-1.50 (4H, m), 0.90(3H, t, J=7.3Hz), 0.87(3H, t, J=7.3Hz)

Claims (9)

  1. The use of a xanthine derivative of the Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of pharmaceutical preparations for use in the treatment of Parkinson's diseases :
    Figure 00720001
    where R1, R2 and R3 are each H, C1-C6 alkyl or allyl; and R4 is a
    Figure 00720002
    group, where Y1 and Y2 are each H or CH3 and Z is an aryl group of 6 to 10 carbons or a heterocyclic group,
    optionally being substituted by up to 3 substituent(s) selected from C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halogen, nitro and amino.
  2. The use according to claim 1, of compounds of formula (I), where Y1 and Y2 are both H.
  3. The use according to claim 1, of compounds of formula (I), where Y1 and Y2 are both H and Z represents a substituted or unsubstituted aryl group, preferably substituted or unsubstituted phenyl.
  4. The use according to claim 1, of compounds of formula (I), where Y1 and Y2 are both H and Z is as defined in claim 3 and R3 is C1-C6 alkyl, preferably methyl, and where, preferably R1 and R2 are each C1-C6 alkyl or allyl.
  5. The use according to claim 1, of compounds of formula (I), where R1 and R2 are each C1-C6 alkyl or allyl, preferably allyl, methyl, ethyl or propyl, R3 is methyl, Y1 and Y2 are both H and Z represents a substituted phenyl group containing from 1 to 3 C1-C6 alkyl or C1-C6 alkoxy substituents, preferably methyl, methoxy or ethoxy.
  6. The use according to claim 1, of compounds of formula (I), where R1, R2, R3 and Y1, Y2 and Z are as defined in claim 5, and where the configuration at position 8 of the xanthine ring is the (E) form.
  7. A compound of the formula (I-a):
    Figure 00740001
    where R1a and R2a are each H, propyl, butyl or allyl;
       R3a is H, C1-C6 alkyl or allyl:
       Za is naphthyl, optionally containing from 1 to 3 substituent(s) selected from C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halogen, nitro and amino, or a
    Figure 00740002
    group, where m is 1, 2 or 3; and
       Y1 and Y2 are each H or CH3; or a
    pharmaceutically acceptable salt thereof.
  8. A compound or salt according to claim 7, where, in said formula (I-a), Za is a
    Figure 00740003
    group where m is 1, 2 or 3; R3a is CH3 and R1a and R2a are both propyl.
  9. A compound or salt according to claim 8, where m is 2.
EP93302780A 1992-04-08 1993-04-08 Therapeutic agents for use in the treatment of Parkinson's Disease Expired - Lifetime EP0565377B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP87115/92 1992-04-08
JP8711592 1992-04-08

Publications (2)

Publication Number Publication Date
EP0565377A1 EP0565377A1 (en) 1993-10-13
EP0565377B1 true EP0565377B1 (en) 1998-01-07

Family

ID=13905960

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93302780A Expired - Lifetime EP0565377B1 (en) 1992-04-08 1993-04-08 Therapeutic agents for use in the treatment of Parkinson's Disease

Country Status (11)

Country Link
EP (1) EP0565377B1 (en)
JP (1) JP2613352B2 (en)
AT (1) ATE161723T1 (en)
BR (1) BR1100636A (en)
CA (1) CA2093403C (en)
DE (1) DE69316067T2 (en)
DK (1) DK0565377T3 (en)
ES (1) ES2112386T3 (en)
GR (1) GR3026233T3 (en)
HK (1) HK1001835A1 (en)
NO (1) NO303265B1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129244B2 (en) 2003-09-18 2006-10-31 Conforma Therapeutics Corporation Triazolopyrimidines and related analogs as HSP90-inhibitors
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US7544672B2 (en) 2005-03-30 2009-06-09 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
WO2020216152A1 (en) * 2019-04-24 2020-10-29 Dongguan Hec New Drug R&D Co., Ltd. 8-substituted aryl vinyl xanthine derivatives and uses thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9302789D0 (en) * 1992-02-19 1994-01-28 Ishida Lot of water-content rice product and process for producinf it
CA2116967C (en) * 1992-07-08 2003-08-19 Fumio Suzuki Antidepressants
JP2613355B2 (en) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 Parkinson's disease treatment
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
EP0711282B1 (en) * 1993-07-28 2002-06-05 Aventis Pharma Limited Compounds as pde iv and tnf inhibitors
DE69526822T2 (en) * 1994-02-23 2003-01-23 Kyowa Hakko Kogyo Kk Xanthine derivatives
SI0958821T1 (en) * 1996-08-07 2005-02-28 Kyowa Hakko Kogyo Co., Ltd. Fat emulsion containing xanthine derivative
ATE325610T1 (en) 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk XANTHINE DERIVATIVES FOR THE TREATMENT OF BRAIN SCHEMIA
RU2367442C2 (en) 2003-04-25 2009-09-20 Новокардия, Инк. Method of urinary normalisation in renal malfunction
EP1709967A4 (en) 2004-01-28 2010-09-15 Kyowa Hakko Kirin Co Ltd Agents for treating migraine
WO2006115690A2 (en) * 2005-04-22 2006-11-02 Novacardia, Inc. Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions
KR20090094465A (en) * 2006-12-22 2009-09-07 슈바르츠 파르마 악티엔게젤샤프트 8-ethinylxanthine derivatives as selective a2a receptor antagonists
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
WO2020125779A1 (en) * 2018-12-21 2020-06-25 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
CN110041331B (en) * 2019-05-17 2020-08-07 广东东阳光药业有限公司 Styrylxanthine derivative and use thereof
CN112409360B (en) * 2019-08-22 2022-12-23 广东东阳光药业有限公司 Heteroaryl vinyl xanthine derivatives and uses thereof
CN112300165B (en) * 2019-11-11 2022-03-04 广东东阳光药业有限公司 8-substituted styrylxanthine derivatives and uses thereof
CN111072663B (en) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-substituted styrylxanthine derivatives and uses thereof
CN111018856B (en) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-substituted styrylxanthine derivatives and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037171C3 (en) * 1969-07-30 1978-05-18 Parke, Davis & Co., Detroit, Mich. (V.St.A.) 7-methyl-8-styryIxanthines and process for their preparation
DE3843117A1 (en) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg NEW XANTHINE DERIVATIVES WITH ADENOSINE ANTAGONISTIC EFFECT
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE4019892A1 (en) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg New xanthine derivs. are selective A1 adenosine antagonists - useful for treating CNS disorders (e.g. senile dementia) and heart and circulation disorders
FR2665636B1 (en) * 1990-08-10 1994-10-07 Adir USE OF A TRIMETHYL-1,3,7 XANTHINE DERIVATIVE FOR THE TREATMENT OF MEMORY DISORDERS, INTELLECTUAL DISORDERS OF SENESCENCE AND ALZHEIMER'S DISEASE.
ATE176470T1 (en) * 1990-10-18 1999-02-15 Kyowa Hakko Kogyo Kk XANTHINE DERIVATIVES

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US7129244B2 (en) 2003-09-18 2006-10-31 Conforma Therapeutics Corporation Triazolopyrimidines and related analogs as HSP90-inhibitors
US7138401B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
US7138402B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation Pyrrolopyrimidines and related analogs as HSP90-inhibitors
US7148228B2 (en) 2003-09-18 2006-12-12 Conforma Therapeutics Corporation Pyrazolopyrimidines and related analogs as HSP90-inhibitors
US7544672B2 (en) 2005-03-30 2009-06-09 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
US8093229B2 (en) * 2005-03-30 2012-01-10 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
WO2020216152A1 (en) * 2019-04-24 2020-10-29 Dongguan Hec New Drug R&D Co., Ltd. 8-substituted aryl vinyl xanthine derivatives and uses thereof

Also Published As

Publication number Publication date
EP0565377A1 (en) 1993-10-13
DE69316067D1 (en) 1998-02-12
CA2093403A1 (en) 1993-10-09
GR3026233T3 (en) 1998-05-29
CA2093403C (en) 1999-08-10
DE69316067T2 (en) 1998-07-02
NO303265B1 (en) 1998-06-22
BR1100636A (en) 2000-04-18
NO931317L (en) 1993-10-11
DK0565377T3 (en) 1998-03-16
HK1001835A1 (en) 1998-07-10
JP2613352B2 (en) 1997-05-28
NO931317D0 (en) 1993-04-06
JPH0616559A (en) 1994-01-25
ES2112386T3 (en) 1998-04-01
ATE161723T1 (en) 1998-01-15

Similar Documents

Publication Publication Date Title
EP0565377B1 (en) Therapeutic agents for use in the treatment of Parkinson&#39;s Disease
EP0628311B1 (en) Xanthine-Derivatives as Antidepressants
EP0590919B1 (en) Therapeutic agents for parkinson&#39;s disease
EP0607607B1 (en) Xanthine derivatives
US5587378A (en) Therapeutic agent for Parkinson&#39;s disease
US6825349B2 (en) A2B adenosine receptor antagonists
EP0698607B1 (en) Xanthine derivative
CA2716788C (en) Deuterium-substituted xanthine derivatives
US20030229106A1 (en) A2B adenosine receptor antagonists
AU2002359365A1 (en) A2B adenosine receptor antagonists
EP1319003A1 (en) Xanthine phosphodiesterase v inhibitors
EP2228375A1 (en) New xanthin derivatives, their production and utilisation as medicine
JP2005516975A (en) 8-heteroarylxanthine adenosine A2B receptor antagonist
US7304070B2 (en) A2B adenosine receptor antagonists
EP1116722A1 (en) [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
EP1234576B1 (en) Pharmaceutical composition for eating disorders
US20060122198A1 (en) Antiepileptic agent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

K1C3 Correction of patent application (complete document) published

Effective date: 19931013

17P Request for examination filed

Effective date: 19940113

17Q First examination report despatched

Effective date: 19940610

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REF Corresponds to:

Ref document number: 161723

Country of ref document: AT

Date of ref document: 19980115

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MICHELI & CIE INGENIEURS-CONSEILS

Ref country code: CH

Ref legal event code: EP

ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

REF Corresponds to:

Ref document number: 69316067

Country of ref document: DE

Date of ref document: 19980212

ET Fr: translation filed
REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2112386

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19980122

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: 78160

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: KYOWA HAKKO KIRIN CO., LTD.

Free format text: KYOWA HAKKO KOGYO CO., LTD.#6-1, OHTEMACHI 1-CHOME,#CHIYODA-KU, TOKYO 100 (JP) -TRANSFER TO- KYOWA HAKKO KIRIN CO., LTD.#1-6-1, OHTEMACHI CHIYODA-KU#TOKYO 100-8185 (JP)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20090429

Year of fee payment: 17

Ref country code: IE

Payment date: 20090423

Year of fee payment: 17

Ref country code: DK

Payment date: 20090415

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20090424

Year of fee payment: 17

NLT1 Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1

Owner name: KYOWA HAKKO KIRIN CO., LTD.

REG Reference to a national code

Ref country code: FR

Ref legal event code: CD

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20100317

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20100325

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20100521

Year of fee payment: 18

Ref country code: ES

Payment date: 20100423

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20100416

Year of fee payment: 18

Ref country code: IT

Payment date: 20100420

Year of fee payment: 18

Ref country code: DE

Payment date: 20100430

Year of fee payment: 18

Ref country code: BE

Payment date: 20100322

Year of fee payment: 18

Ref country code: AT

Payment date: 20100413

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20100414

Year of fee payment: 18

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20100409

Year of fee payment: 18

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20100322

Year of fee payment: 18

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100503

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20111010

BERE Be: lapsed

Owner name: KYOWA HAKKO KIRIN CO. LTD

Effective date: 20110430

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69316067

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69316067

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20111101

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110408

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 161723

Country of ref document: AT

Kind code of ref document: T

Effective date: 20110408

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 980400413

Country of ref document: GR

Effective date: 20111102

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20111230

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110502

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111101

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111010

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110408

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110408

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110408

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111102

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20120604

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110409

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110409

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111031